Induced Pluripotent Stem Cells in Dental and Nondental Tissue Regeneration: A Review of an Unexploited Potential

Israa Ahmed Radwan, Dina Rady, Marwa M. S. Abbass, Sara El Moshy, Nermeen AbuBakr, Christof E. Dörfer, and Karim M. Fawzy El-Sayed

1Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt
2Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo University, Cairo, Egypt
3Clinic for Conservative Dentistry and Periodontology, School of Dental Medicine, Christian Albrechts University, Kiel, Germany
4Oral Medicine and Periodontology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt

Correspondence should be addressed to Karim M. Fawzy El-Sayed; karim.fawzy@gmail.com

Received 5 December 2019; Accepted 6 March 2020; Published 29 March 2020

Copyright © 2020 Israa Ahmed Radwan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cell-based therapies currently represent the state of art for tissue regenerative treatment approaches for various diseases and disorders. Induced pluripotent stem cells (iPSCs), reprogrammed from adult somatic cells, using vectors carrying definite transcription factors, have manifested a breakthrough in regenerative medicine, relying on their pluripotent nature and ease of generation in large amounts from various dental and nondental tissues. In addition to their potential applications in regenerative medicine and dentistry, iPSCs can also be used in disease modeling and drug testing for personalized medicine. The current review discusses various techniques for the production of iPSC-derived osteogenic and odontogenic progenitors, the therapeutic applications of iPSCs, and their regenerative potential in vivo and in vitro. Through the present review, we aim to explore the potential applications of iPSCs in dental and nondental tissue regeneration and to highlight different protocols used for the generation of different tissues and cell lines from iPSCs.

1. Introduction

Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of the blastocyst. They can give rise to tissues derived from the three germ layers and are regarded as a renewable potent cell source for the regeneration of all body tissues [1–4]. However, ES usage in regenerative medicine faces a lot of obstacles as their isolation requires destruction of human embryos which raises justified ethical objections. ES can also elicit an immune response upon transplantation in patients [5]. In 2006, Takahashi et al. [6] demonstrated that mature differentiated cells can be reprogrammed and dedifferentiated into embryonic-like cells, with ES-like properties. Mature murine fibroblast cell lines were reversed into pluripotency via retroviral transduction of 4 transcription factors, POU domain class 5 transcription factor 1 (Oct3/4), the sex-determining region Y-box2 (Sox2), Kruppel-like factor 4 (Klf4), and myelocytomatosis oncogene (c-Myc), giving rise to induced pluripotent stem cells (iPSCs). Those four transcription factors (also referred to as OSKM factors) were postulated to be responsible for the maintenance of ES inherent pluripotency. Over the subsequent years, iPSCs were generated from a variety of adult tissues [7–9] and were similar to ES in morphology, proliferative rates, surface antigens, expressed genes, and in vivo teratoma formation [6].

2. iPSC Source and Generation (Reprogramming) Methods

iPSCs were successfully generated from different dental and nondental tissues (Figure 1) including fibroblasts, keratinocytes, melanocyte blood cells, bone marrow cells, adipocyte cells, tissue-resident progenitor cells, and gingival and
periodontal ligament fibroblasts [10–13] via transduction of Oct3/4, Sox2, and Klf4 [14, 15]. iPSCs were also successfully generated from dental pulp stem cells (DPSCs) [16–18], stem cells from human exfoliated deciduous teeth (SHED) [18, 19], and stem cells from apical dental papilla [18]. Gingival fibroblast-derived iPSCs were considered to be advantageous over dermal fibroblasts (DF) as they could be easily acquired during routine dental treatment and were effectively reprogrammed into iPSCs [14].

As mentioned above, generation of iPSCs depends on the transduction of specific transcription factors into the somatic cell genome via vectors for its reprogramming [20]. Vectors used during the generation of iPSCs can be divided into integrative viral vectors, integrative free vectors, and nonviral vectors [21]. Originally, lentivirus (a retrovirus), an integrating viral vector, was used for iPSC generation with high reprogramming efficacy [6]. Despite offering a high transduction ability, integrating viral vectors insert their whole genome into recipient cells and may introduce oncogenes or genetic mutations into the host cells [22] (Figure 1).

Nonintegrating viruses, such as Sendai virus and adenovirus, were subsequently introduced in an attempt to overcome these drawbacks [23]. Tashiro et al. [24] compared four types of promoters (RSV, CMV, cytomegalovirus enhancer/b-actin (CA), and elongation factor-1a (EF-1a)) using adenovirus vectors for iPSC induction. An adenovirus vector containing EF-1a and CA promoter efficiently transduced transgenes into mouse iPSCs, without a decrease in pluripotency or viability. An optimized adenovirus vector that was developed by the authors enhanced adipocyte and osteoblast differentiation, confirmed by significant gene expressions of peroxisome proliferator-activated receptor c and runt-related transcription factor 2 (RUNX2), respectively, by iPSCs.

To avoid an increased risk of tumor generation and chromosomal instability, nonviral vectors were subsequently introduced for the somatic reprogramming process, including proteins, plasmid, piggyBac transposon, minicircle vector, miRNA, and mRNA [25–30]. Gene-editing technologies like CRISPR/Cas9, zinc finger nucleases, and transcription activator-like effector nucleases (TALENs) were additionally employed for genome editing of iPSCs to introduce certain traits for disease modeling and cancer research or to alter their gene expression for possible application in the field of regenerative medicine [31].

3. Assessment of Pluripotency

Following iPSC generation, cells have to be assessed via pluripotency assays, including morphological and histological analysis, and certain gene expressions, proving their ability to differentiate into tissues derived from the three germ layers
and teratoma formation [32]. Teratoma assays involve injection of iPSCs into immunocompromised experimental animals and subsequent formed tissue analysis to assure teratoma formation [33]. Alternatively, in vitro embryoid body (EB) generation can be used to ascertain pluripotency; EB is a mass of cells derived from all three germ layers [32], generated from iPSCs upon culturing in proper media [32, 34, 35]. EB generation encompasses the homogeneous method as the liquid suspension method and the heterogeneous method as the hanging drop culture. While the heterogeneous method is considered the easiest way to generate EB, the resulting cell masses are largely heterogeneous in size [36], which are irreproducible [37] and negatively affect subsequent iPSC differentiation towards a specific cell line [38]. The homogeneous method, on the other hand, creates cell masses of more homogeneous, uniform sizes that subsequently enhance cell viability and facilitate their subsequent differentiation into specific cell lines [33, 39]. To avoid tumor formation, prior to implantation, iPSCs are either differentiated into mesenchymal stem cells (MSCs) or targeted tissue cell types with or without EB formation (Figure 1).

4. iPSCs in Dental and Nondental Tissue Regeneration (Table 1)

4.1. iPSCs and Bone Regeneration. Although autogenous bone graft remains to be the gold standard for reconstruction of bone defects [40], it carries the risk of bone resorption and donor site infection and the graft may not always be available in sufficient amounts [41]. iPSC technologies may provide a suitable alternative to autogenous grafting, whereby patients’ somatic cells are induced into bone-forming cells that are loaded on an appropriate scaffold in combination with proper bioactive molecules for bone tissue engineering [42].

To induce osteogenic differentiation of iPSCs, a variety of agents were proposed in isolation or combination, including osteogenic media, ascorbic acid, b-glycerophosphate, dexamethasone, bone morphogenetic proteins (BMPs), and vitamin D3 [43–46]. Osteogenic differentiation is followed by proper characterization of generated bone cells through their expression of osteogenesis-related genes (RUNX2, osteopontin (OPN), osterix (OSX), osteocalcin (OCN), and collagen type I (COL1A1)) [47–50] in addition to the evaluation of in vitro mineralization and alkaline phosphatase (ALP) activity [51, 52].

Osteogenic potential of human iPSCs was demonstrated on polymeric nanofibrous polyethersulfone (PES) scaffold with upregulated expressions of osteogenic genes and alkaline phosphatase activity in vitro [48, 53]. The expression of key osteoblast-related genes in undifferentiated iPSCs was nearly 30 times higher than in undifferentiated ES cells. On the contrary, the expression of the same genes in ES- and iPSC-derived osteoblasts was not significantly different except for OPN and COL1A1, which were significantly higher in iPSC-derived osteoblasts [51]. Evidence revealed that ES cells and iPSCs generated from transgenic mice expressing rat 2.3 kb type I collagen promoter-driven green fluorescent protein (Col2.3GFP) successfully differentiated into osteoblast lineage cells that expressed Col2.3GFP in vitro [54]. Gene expression profiles proved that ES- and iPSC-derived osteoblasts resemble osteoblasts present in the calvaria [54].

The osteoinductive properties of iPSC-derived bone cells and their capability in treating bone defects were further assessed in vivo by their implantation into a severe combined immunodeficiency (SCID) mouse model. Bone formation was confirmed four weeks following implantation by soft X-ray images [43], X-ray microcomputed tomography (μCT) [55], cone beam computed tomography imaging [49], and histological tissue specimens [43, 47–52]. In a cleidocranial dysostosis model, the mutation in RUNX2 gene was repaired in iPSCs derived from mucosal tissues of affected patients. The reverted cells revealed marked upregulation of osteoblast differentiation markers after being cultured in OM for nine days. Loading the differentiated osteoblasts originating from iPSCs with a corrected mutation on a peptide nanofiber scaffold and implanting them into SCID rats’ calvarial bone defects revealed reossification four weeks after transplantation with a significant increase in bone volume and bone mineral content [52]. Similarly, osteogenic cells differentiating from EB derived from iPSCs showed positive results in bone regeneration and healing following implantation in the rats’ critical-sized calvarial defect [53, 56, 57] and long bone segmental defect rat model [57] after being loaded on polymeric nanofibrous PES scaffold [53], fibrin glue scaffold [57], hydroxyapatite (HA)/tricalcium phosphate scaffold [57], or self-assembling peptide nanofiber hydrogel scaffold [56]. Moreover, iPSCs differentiated into functional osteoblasts and demonstrated a bone regenerative effect comparable to human bone marrow-(BM-) MSCs in vivo [57].

4.1.1. Osteogenic Potential of iPSCs-MSCs Obtained through EB Formation. This method entails the differentiation of MSCs from EB-derived iPSCs. It was suggested to possess notable advantages over direct differentiation of iPSCs into osteoblasts, with the resulting osteogenic cells demonstrating a significant upregulation of osteoblast-related genes including ALP, RUNX2, COL1A1, and OCN [58, 59]. Several factors were demonstrated to influence the osteogenic potential of iPSC-derived MSCs including the incorporation of retinoic acid, transforming growth factor-beta (TGF-β) [60, 61], or metformin into the culture media [62] as well as co-seeding with other cell types [63–65]. The suspension time of EB and genetic modification of iPSCs-MSCs also proved to affect their osteogenic capability [66–68]. Culturing EB generated from dermal fibroblast iPSCs in media supplemented with TGF-β induced MSC differentiation. Two populations of MSCs were recognized, early MSCs that migrated from EB during days 2–5 and late MSCs that crawled from EB during days 5–8. The two iPSC-derived MSC populations and BM-MSCs were transduced with BMP-6 plasmid. Resulting cells were either suspended in fibrin gel and injected into thigh muscles of SCID rats or loaded on collagen scaffolds and implanted in a nonunion radial fracture SCID rat model. No or limited bone formation was acquired upon ectopic injection of BMP-6-late MSCs,
### Table 1: Studies investigating the regenerative potential of iPSCs.

| Authors, year  | Cell source                          | Study model | Scaffold                        | Outcome                                                                                     |
|----------------|--------------------------------------|-------------|---------------------------------|---------------------------------------------------------------------------------------------|
| Bone           |                                      |             |                                 | CA promoter potently transduced iPSCs with enhanced osteogenic differentiation.               |
| Tashiro et al., 2009 [24] | 20D17, 38C2, and stm99-1 from mouse EF | In vitro    | —                               | Resveratrol had antiapoptotic effect and enhanced osteogenic differentiation of iPSCs.        |
| Kao et al., 2010 [112] | Murine germ line-competent from rat EF | In vitro    | —                               | Retinoic acid and TGF-β enhanced osteogenic differentiation of iPSCs.                        |
| Li et al., 2010 [60] | Mouse tail-tip fibroblasts        | In vitro    | —                               | SATB2 facilitated iPSC differentiation towards osteoblast lineage cells with enhanced bone formation and mineralization. |
| Bilousova et al., 2011 [81] | Mouse dermal fibroblasts            | In vitro    | 3D gelatin scaffold              | 3D gelatin scaffold enhanced functional osteoblastic differentiation of iPSCs.               |
| Ye et al., 2011 [104] | Mouse tail-tip fibroblasts           | In vitro    | Silk scaffolds                   |                                               |
| Hayashi et al., 2012 [43] | iPS-MEF-Ng-20D-17                   | In vitro    | PES scaffolds                    | 2 Gray irradiation prior to transplantation inhibited teratoma formation.                    |
| Levi et al., 2012 [100] | Human adipose-derived stromal cells | In vivo     | HA-coated, BMP-2–releasing PLA scaffold | HA-coated, BMP-2–releasing PLA scaffold promoted osteogenesis.                                |
| Li and Niyibizi, 2012 [61] | Murine tail-tip fibroblasts         | In vitro    | HA/TCP scaffolds                 | TGF-β promoted iPSC-derived EBs towards osteogenic lineage.                                  |
| Villa-Diaz et al., 2012 [165] | Human fibroblasts                   | In vitro    | Poly [2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide] scaffold | hiPSCs cultured in a xeno-free system can differentiate into MSCs and form bone in vivo.   |
| Ardestiri et al., 2013 [53] | Human iPSC line                     | In vitro    | PES scaffolds                    | Plasma-treated PES scaffolds promoted osteogenic differentiation of iPSCs.                  |
| Ardestiri et al., 2013 [48] | Human iPSC line                     | In vitro    | PES scaffolds                    | PES scaffold enhanced differentiation of iPSCs into osteoblast-like cells.                   |
| de Peppo et al., 2013 [86] | 11C and 1013A iPSC (dermal fibroblast), BC1-iPSC (bone marrow) | In vitro    | Decellularized bone scaffold     | Different reprogramming methods can influence osteogenic potential of iPSCs.               |
| Jin et al., 2013 [106] | Cat SC101AiPSC                      | In vitro    | Macrochannelled PCL scaffolds    | iPSCs exhibited in vitro transcription and translation of osteogenesis-related molecules and in vivo bone induction. |
| Liu et al., 2013 [66] | Human B1 cell line                  | In vitro    | CPC immobilized with RGD (Arg-Gly-Asp) | iPSCs transduced with BMP-2 showed enhanced osteogenic differentiation.                     |
| Nasu et al., 2013 [91] | Human BMSCs and DFs                 | In vitro    | —                               | No difference was noticed in chondrogenic and osteogenic differentiation of iPSCs from different origins. |
| Authors, year | Cell source | Study model | Scaffold | Outcome |
|--------------|-------------|-------------|---------|---------|
| Thein Han et al., 2013 [72] | Human BC1 cell line | In vitro | Biofunctionalized CPC | Biofunctionalized CPC enhanced osteogenic differentiation and mineralization. |
| Zou et al., 2013 [90] | Human fibroblast | In vitro | PCL or PHT | Increased ALP activity and calcium deposition on PHT scaffold in vitro as well as ectopic bone formation in vivo in comparison to PCL. |
| Ardeshrilajim et al., 2014 [97] | Human fibroblast iPSC lines | In vivo | — | iPSCs showed a higher capacity for osteogenic differentiation compared to AT-MSCs. |
| Dogaki et al., 2014 [93] | Mouse embryonic fibroblast | In vitro | — | iPSCs revealed higher osteogenic differentiation capability in comparison to BM-MSCs. |
| Hong et al., 2014 [87] | Rhesus macaques’ BMSCs, skin fibroblasts, and CD34+ cells | In vitro | HA/TCP | iPSCs demonstrated robust bone formation. |
| Hynes et al., 2014 [88] | Gingival fibroblasts, periodontal ligament cells, and human lung | In vitro | HA/TCP | iPSCs derived from PDL showed a superior capability to form mature bone. |
| Lee et al., 2014 [58] | Human fibroblasts | In vitro | — | MSC CM enhanced osteogenic differentiation of iPSCs. |
| Liu et al., 2014 [67] | Human BC1 cell line | In vitro | CPC immobilized with RGD | NELL1 gene overexpression enhanced osteogenesis. |
| Kang et al., 2014 [89] | Human fibroblast | In vitro | PCL or PCL-nHA | Increased expression of osteogenic genes in both OC scaffolds was highly expressed in PCL-nHA in comparison to PCL scaffolds. |
| Kang et al., 2014 [107] | IMR90p18-iPS | In vitro | Mineralized gelatin methacrylate-based matrices | Osteogenic differentiation of hiPSCs was achieved through biomaterial-based cues alone. |
| Kanke et al., 2014 [114] | Human neonatal dermal fibroblasts Mouse fibroblasts | In vitro | — | An effective strategy for differentiation of mESCs, mPSCs, and hiPSCs into osteoblasts was devised. |
| Ko et al., 2014 [57] | Human iPSC line (SC802A-1) | In vivo | HA/b-tricalcium phosphate scaffold Fibrin glue scaffold | iPSCs differentiated into functional osteoblasts and demonstrated bone regenerative effect comparable to human BM-MSCs in vivo. Osteoinduced hiPSCs showed relatively lower and delayed expressions of the osteogenic marker in vitro. |
| Ochiai-Shino et al., 2014 [109] | Human iPSCs (line 201B7) from adult fibroblasts | In vitro | — | TNAP-positive cell hiPSC-derived EBs expressed high levels of osteogenic genes. |
| Phillips et al., 2014 [99] | Human SFs (NIHI2 and NIHI7) | In vitro | HA/TCP | BM-MSCs cultured on HA/TCP promoted bone formation. |
| Tang et al., 2014 [77] | BC1 cell line | In vitro | CPC | CPC scaffold promoted osteoblastic differentiation. |
| Authors, year     | Cell source                        | Study model | Scaffold | Outcome                                                                 |
|------------------|------------------------------------|-------------|----------|--------------------------------------------------------------------------|
| Wu et al., 2014  | Tail-tip mouse fibroblasts          | In vitro    | CCHS     | Alox5 affects the osteogenic and adipogenic abilities of iPSCs.          |
| Ardeshirylajimi and Soleimani, 2015 | Human iPSC line                    | In vitro    | —        | Combination of OM and ELF-EMF promoted bone differentiation.             |
| Ishiy et al., 2015 | SHED and human dermal fibroblast   | In vitro    | —        | Osteogenic potential of SHED-iPSCs and iPSCs-fibroblasts-iPSCs is higher than osteoinduced SHED. |
| Ji et al., 2015   | Human gingival fibroblasts          | In vitro    | nHA/CG scaffolds | Sphere-nHA/CG increased iPSC osteogenic differentiation and bone formation. |
| Kang et al., 2015 | Human dermal fibroblast            | In vitro    | —        | iPSCs showed osteogenic efficacy comparable to BM-MSCs.                  |
| Lepage et al., 2016 | Equine fibroblast                  | In vitro    | —        | iPSCs showed early mineralization indicating early osteogenesis.          |
| Wang et al., 2015 | BC1 cell line                      | In vitro    | RGD-coated macroporous CPC | Enhanced osteogenic differentiation of iPSCs.                          |
| Wang et al., 2015 | Umbilical cord mesenchymal cells    | In vitro    | Synthetic peptide-decorated 2D microenvironment via pDA chemistry and CMC | Peptide-decorated niche promoted osteogenic differentiation of human iPSCs. |
| Hayashi et al., 2016 | Human iPSCs (line 201B7)           | In vivo     | Peptide nanofiber hydrogel scaffold | Increased bone regeneration using iPSCs delivered in the nanofiber scaffold. |
| Jeon et al., 2016 | Dermal fibroblasts                 | In vitro    | PLGA/PLLA | 3D biomaterials promoted osteogenic differentiation of iPSCs.           |
| Ji et al., 2016   | Human gingival fibroblasts          | In vitro    | HCG      | Osteogenic differentiation of hiPSCs was improved by HCG scaffold.       |
| Kang et al., 2016 | IMR90p18-iPS cell line             | In vitro    | Macroporous synthetic matrices | Adenosine induced hiPSC differentiation into functional osteoblasts. |
| Sheyn et al., 2016 | Dermal fibroblasts                 | In vitro    | —        | Genetic modification of iPSCs-MSCs and the suspension time of EB can effectively influence bone regeneration. |
| Sladkova et al., 2016 | 1013A cell line obtained from dermal fibroblasts | In vitro    | Macroporous CPC using PEG particle | Enhanced osteogenic differentiation.                                    |
| Wang et al., 2016 | Human BC1 cell line                | In vitro    | Injectable CPC with hydrogel fibers | Injectable CPC with hydrogel fibers promoted osteogenesis.          |
| Wang et al., 2016 | BCI cell line and clone 1 from human foreskin fibroblast | In vitro    | Injectable CPC with hydrogel fibers | Injectable CPC with cell-encapsulating hydrogel fibers was associated with enhanced bone regeneration. |
| Authors, year | Cell source | Study model | Scaffold | Outcome |
|--------------|-------------|-------------|----------|---------|
| Wang et al., 2016 [69] | Human BC1 cell line | In vitro | CPC alginate microbeads | Osteoinduction or transduction with BMP-2 promoted osteogenic differentiation. |
| Xie et al., 2016 [74] | Mouse MiPS-01 cell line | In vitro | Biomimetic nanofiber HA/Col/CTS | Biomimetic nanofiber HA/Col/CTS was associated with upregulation of osteogenic genes. |
| Zhang et al., 2016 [85] | Human foreskin fibroblasts | In vitro | Porous β-TCF | Dimethylxaloylglycine promoted iPSC angiogenesis. |
| Chijimatsu et al., 2017 [92] | Mouse neural crest cells | In vitro | — | iPSCs failed to repair rat osteochondral knee defects although chondrogenic and osteogenic capacity in vitro was comparable to human BM-MSCs. |
| Deng et al., 2017 [101] | hNF-C1 line obtained from dermal fibroblasts | In vitro | Peptide-conjugated nanofiber scaffold | Nanofiber scaffolds facilitated osteodifferentiation of hiPSCs. |
| Liu et al., 2017 [64] | Human BC1 cell line | In vitro | CPC | HUVECs promoted mineralization of iPSCs. |
| Ma et al., 2017 [51] | E14 mouse embryonic fibroblasts | In vitro | — | ES and iPSCs were similar in their osteogenic differentiation potential. |
| Zhang et al., 2017 [65] | Human BC1 cell line | In vitro | CPC | HUVECs and pericytes promoted mineralization of iPSCs. |
| Chen et al., 2018 [63] | Human BC1 cell line | In vitro | CPC | HUVECs promoted mineralization of iPSCs. |
| Oudina et al., 2018 [122] | Human adult myoblasts | In vitro | Coral scaffold | Undifferentiated hiPSC implantation promoted the formation of bone-like structures of murine origin. |
| Saito et al., 2018 [52] | Oral mucosa of 2 CCD patients | In vitro | Peptide nanofiber scaffold | Repairing RUNX2 mutation in iPSCs-CCD promoted osteogenesis. |
| Wang et al., 2018 [62] | Human BC1 cell line | In vitro | CPC | Metformin promoted osteogenic differentiation of iPSCs. |
| Wu et al., 2018 [70] | Human foreskin fibroblasts | In vitro | Injectable alginate microbeads | 3G7 promoted antibody-mediated osseous regeneration. |
| Abazari et al., 2019 [120] | Human iPSC line | In vitro | PVDF/Col/PRP scaffolds | PRP-incorporated PVDF/col promoted iPSC osteogenesis. |
| Abazari et al., 2019 [47] | Human iPSC line | In vitro | PCL-PVDF (bFGF) | Incorporating bFGF in PCL-PVDF scaffolds promoted osteogenesis. |
| Al-Wahabi et al., 2019 [75] | Mouse MEF-NG-20D-17 cell line | In vitro | Polystyrene substrate | Different scaffold topography enhanced osteogenic differentiation. |
| Hosseini et al., 2019 [117] | Human iPSC line from HEK293T cells | In vitro | PHBV nanofiber scaffold | Nanofiber-based PHBV increased osteogenic differentiation. |
| Authors, year | Cell source | Study model | Scaffold | Outcome |
|---------------|-------------|-------------|----------|---------|
| Hosseini et al., 2019 [118] | Human iPSC line from HEK293T cells 414C2 and 409B2: human fibroblasts | In vitro | PCL-PLLA (poly-P) electrospun scaffolds | Poly-P in PCL-PLLA enhanced osteogenesis. |
| Kawai et al., 2019 [103] | 1231A3: human PBMC 317-12: human fibroblast OI#1: skin fibroblasts OI#2: skin fibroblasts | In vitro | — | Retinoic acid induced the osteogenic differentiation iPSCs and bone formation. |
| Mao et al., 2019 [98] | Adipose-derived stem cells | In vivo | nHP gelatin cryogel scaffolds | ASC-iPSCs showed osteogenic differentiation. |
| Mirzaei et al., 2019 [116] | Human iPSC line from HEK293T cells | In vitro | 2D and 3D PVDF | 3D scaffold enhanced differentiation of bone-forming cells. |
| Ramaraju and Kohn, 2019 [71] | Human fibroblasts | In vitro | Mineralized scaffolds coated with DIP-VTK | Enhanced osteogenesis and angiogenesis |
| Saburi et al., 2019 [119] | Human iPSC line from HEK293T cells | In vitro | GO-PVDF | GO significantly improved osteoconductivity of the PVDF. |
| Sladkova et al., 2019 [108] | Mesenchymal progenitors derived from pluripotent stem cell line 1013A (1013A-MPs) | In vitro | Decellularized cow and human bone scaffolds | Both scaffolds equally supported cell viability, tissue growth, and formation of mineralized bone matrix. |
| Tahmasebi et al., 2019 [50] | Human iPS cell line | In vitro | PCL nanofibers with miRNA-22 and miRNA-126 | miRNAs incorporated in PCL scaffold promoted osteogenesis. |
| Xu et al., 2019 [55] | Human fibroblasts | In vitro | HA derived from PLCL with peptide H1 in a core silk fibrin | Increased proliferation and osteogenic differentiation of iPSCs as well as fast bone formation in vivo |
| Zhong et al., 2019 [59] | Murine iPSCs derived from MiPS-01 | In vitro | — | Osteoblast conditioned medium enhanced osteogenic differentiation. |
| Zhu et al., 2019 [54] | Human embryonic kidney line 293T | In vitro | — | Gene profiles of ESC and iPSC-derived osteoblasts are similar. |
| Salivary glands | | | | |
| Alaa El-Din et al., 2019 [123] | Human skin fibroblasts | In vitro | — | iPSCs treated salivary gland carcinomas. |
| Ono et al., 2015 [124] | Stomach cells | In vitro | — | iPSCs accelerated salivary gland development and regeneration. |
| Periodontal tissues | | | | |
| Duan et al., 2011 [127] | iPSCs (foreskin)-1-DL-1 from human foreskin fibroblasts | In vitro | Silk scaffold | EMD combined with iPSCs enhanced periodontal tissue regeneration. |
| Hynes et al., 2013 [132] | Human foreskin | In vitro | Fibrinogen and thrombin | iPSCs-MSCs enhanced periodontal tissue regeneration. |
| Authors, year | Cell source | Study model | Scaffold | Outcome |
|--------------|-------------|-------------|----------|---------|
| Yang et al., 2014 [134] | Rat embryonic fibroblasts | In vitro | — | iPSCs transduced with TSG-6 were associated with decreased inflammation and alveolar bone loss. |
| Yin et al., 2016 [128] | Human gingival fibroblasts | In vitro | — | EMD and GDF-5 induced periodontal differentiation of iPSCs. |
| Li et al., 2017 [131] | Human gingival fibroblasts | In vitro | — | Increasing culturing time had no effect on periodontal differentiation potential of iPSCs. |
| Yin et al., 2017 [129] | Peripheral blood mononuclear cells | In vitro | Hyaluronic acid hydrogels | rhGDF-5 promoted periodontal differentiation of iPSCs-MSCs. |
| Chien et al., 2018 [130] | Rat fibroblasts | In vitro | G/C/GP hydrogel phosphate | BMP-6-iPSCs on hydrogel scaffold promoted periodontal tissue regeneration. |
| Hamano et al., 2018 [126] | Skin fibroblasts | In vitro | — | iPSC-NCLC-PDL cells showed upregulated expression of periodontal tissue-related genes. |
| Hynes et al., 2018 [133] | Tail-tip fibroblasts from NOD/Lt mice | In vitro | — | iPSCs decreased inflammation and periodontal tissue destruction. |
| Li et al., 2018 [125] | Human gingival fibroblasts and human neonatal skin fibroblast | In vitro | Hydrogel | Gingival iPSCs demonstrated better expression of periodontal cells’ markers. |

**Enamel**

| Authors, year | Cell source | Study model | Scaffold | Outcome |
|--------------|-------------|-------------|----------|---------|
| Arakaki et al., 2012 [135] | Mouse embryonic fibroblast | In vitro | — | iPSCs cocultured with dental epithelial cells differentiated into ameloblasts. |
| Yoshida et al., 2015 [136] | Mouse embryonic fibroblast | In vitro | — | iPSCs differentiated into ameloblast-like cells cultured with epithelial cell rests of Malassez cell conditioned medium and gelatin-coated dishes. |
| Abdullah et al., 2019 [137] | Mouse embryonic fibroblast | In vitro | — | Neurotrophin-4 in addition to iPSCs promoted its differentiation into dental epithelial-like cells. |

**Dentin pulp complex**

| Authors, year | Cell source | Study model | Scaffold | Outcome |
|--------------|-------------|-------------|----------|---------|
| Otsu et al., 2012 [140] | Mouse embryonic fibroblast | In vitro | — | iPSCs differentiated into NCLC could further differentiate into iPSC-derived dental mesenchymal cells including odontoblasts. |
| Ozeki et al., 2013 [138] | Mouse embryonic fibroblast | In vitro | Collagen type I scaffold combined with BMP-4 | iPSCs differentiated into functional odontoblast-like cells. |
| Ozeki et al., 2015 [139] | Mouse iPSC line (iPS-MEF-Ng-20D-17) | In vitro | — | Treatment with inorganic polyphosphate induced MMP-3 that physiologically accelerated both the proliferation and differentiation of odontoblast-like cells derived from iPSCs. |
| Seki et al., 2015 [141] | Mouse iPSCs | In vitro | — | Gene transfection of Pax9 and BMP-4 into iPSC-derived NCLCs promoted their differentiation into odontoblast-like cells. |
| Authors, year        | Cell source                  | Study model | Scaffold                      | Outcome                                                                                                                                                                                                 |
|----------------------|------------------------------|-------------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Xie et al., 2018 [142] | Dental pulp stem cells       | In vitro    | Dentin discs with PLA scaffolds | iPSCs cultured on dentin discs with PLA scaffolds formed pulp-like tissue with the presence of tubular dentin.                                                                                           |
| Whole tooth regeneration |
| Wen et al., 2012 [145]    | Mouse embryonic fibroblast  | In vitro    | Collagen hemisphere            | iPSCs combined with epithelial and mesenchymal cells formed bone and dental pulp-like structures.                                                                                                        |
| Cai et al., 2013 [143]    | Human urine cells            | In vitro    | —                             | iPSCs cocultured with mouse dental mesenchyme formed tooth-like structure.                                                                                                                               |
| Liu et al., 2016 [144]   | Mouse iPSC line (C5 cell line)| In vitro    | Fibrin gel                    | iPSCs cultured in ameloblast serum-free conditioned medium supplemented with BMP-4 differentiated into ameloblast- and odontoblast-like cells. Ameloblasts serum-free CM increased the gene and protein expression of enamelin, ameloblastin, and CK-14, as well as phosphorylated Smad1/5, p38 MAPK, and ERK1/2 MAPK in iPSCs as compared with iPSCs cultured in epithelial cell medium for 14 days. |
| Liu et al., 2020 [146]   | Mouse iPSC line (C5 cell line)| In vitro    | —                             |                                                                                                                                                                                                       |
while opposite results were obtained upon injecting BMP-6-
early MSCs. It was concluded that iPSCs-MSCs obtained at
early EB suspension time possessed a more pronounced stem
cell phenotype and were capable of ectopic bone formation,
whereas those cells obtained later acquired a more differenti-
ated phenotype of osteoblasts and were capable of significant
bone formation in vivo [68].

Similarly, genetic modification of human iPSCs-MSCs by
either BMP-2 or NELL1 overexpression, followed by seeding
of the modified cells on calcium phosphate cement (CPC)
scaffold immobilized with RGD (Arg-Gly-Asp), showed sig-
ificantly high expression of RUNX2, OCN, and COL1A1
[66, 67]. Additionally, human iPSCs-MSCs that were either
osteinduced or transduced with BMP-2 demonstrated high
expression levels of osteoblast-related genes [69]. Incorporat-
ing retinoic acid combined with TGF-β1 or TGF-β1 into
murine iPSC-derived EB culture media enhanced mineraliza-
tion and osteogenic differentiation [60, 61]. Additionally,
human iPSCs-MSCs cultured in the presence of metformin
and seeded on CPC scaffolds showed upregulated expression
of osteoblast-related genes and proteins as well as increased
mineralization. Induction of adenosine monophosphate-(AMP-)
activated protein kinase phosphorylation concomi-
tant with increased RUNX2 expression was also evident
[62]. Moreover, coculturing of human iPSCs-MSCs with
human umbilical vein endothelial cells (HUVECs) on CPC
scaffolds [63, 64] or coculturing with pericytes [65] enhanced
osteogenesis and vascularization in vitro and in vivo with
an upregulation expression of osteogenic (ALP, OCN, and
COL1A1) and angiogenic genes (vascular endothelial growth
factor (VEGF) and vascular endothelial cadherin).

Antibody-mediated osseous regeneration was recently
described to impact in vivo bone regeneration. Human
iPSCs-MSCs were combined with 3G7, an anti-BMP-2
antibody, that were hypothesized to facilitate the engage-
ment of BMP-2 to their receptors on iPSCs-MSCs. 3G7 and
iPSCs-MSCs were subsequently loaded on biocompat-
ible, biodegradable alginate microbeads that were injected
subcutaneously in rats. In vivo enhanced bone formation,
mineralization, and vascularization associated with in vitro
enhanced osteogenic differentiation were mediated through
activation of the BMP-2/Smad1/RUNX2 pathway [70].

Biofunctionalization of the scaffold was further suggested
to promote human iPSCs-MSCs osteogenic differentiation
and vascularization, where human iPSCs-MSCs seeded on
CPC scaffolds, treated with biofunctional agents and bioac-
tive peptides [71–73] as well as murine iPSCs-MSCs seeded
on biomimetic nanofibers of hydroxyapatite/collagen/chito-
san (HA/COL/CTS), showed upregulation of RUNX2, OSX,
ALP, and COL1A1 gene expression levels [74]. Furthermore,
outgrowing cells from mouse iPSCs cultured on different
polystyrene substrate topographies displayed upregulation
of COL1A1 and RUNX2 [75]. Human iPSCs-MSCs seeded on
microporous CPC scaffolds using polyethylene glycol (PEG)
particles showed upregulation of RUNX2, COL1A1, ALP, OCN,
and platelet-derived growth factor receptor-beta (PDGF-R-β)
[76]. Similarly, human iPSCs-MSCs seeded on CPC [62, 77–79]
or poly lactic-co-glycolic acid/poly L-lactic acid (PLGA/PLLA)
scaffold combined with macrophages
[80] or fast degradable alginate microbeads [69] showed high
expression of osteoblast-related genes. Moreover, murine
iPSC-derived MSCs seeded onto three-dimensional gelatin
scaffold revealed upregulation of several osteoblast-related
genes in vitro and in vivo, following subcutaneous implanta-
tion in rats [81]. Demonstrating the key role of osteoprote-
erin/receptor activator of nuclear factor κB ligand
(ORP/RANKL) in orchestrating osteoblastic and osteoclastic
action in bone remodeling, human iPSCs-MSCs were
cocultured with iPSCs-macrophages committed to osteo-
blastogenesis and osteoclastogenesis, respectively, on HA-
based PLGA/PLLA 3D scaffolds. Enhanced expression of
bone-related genes upon monoculturing human iPSCs-
MSCs on HA-5 PLGA/PLLA was demonstrated as compared to
HA-0 PLGA/PLLA. Coculturing induced upregulated
expression of late osteogenic markers (OPN and OCN) and
downregulated expression of early osteogenic markers
(COL1A1, ALP, and RUNX2). Similar results were attained
in vivo through implantation of HA-PLGA/PLLA scaffold
loaded with human iPSCs-MSCs and iPSCs-macrophages
subcutaneously in rodents [80].

4.1.2. Osteogenic Potential of iPSCs-MSCs Obtained without
EB Formation. Another method proposed to obtain iPSCs-
MSCs relies on the dissociation of iPSC colonies, without
prior formation of EB, into a single cell suspension.
The resulting cells are characterized as MSCs, either through flow
cytometry or through cell passaging protocols, followed by
osteogenic differentiation [82–84]. Dimethylsulfoxoyglyclycine
(DMOG) promoted iPSCs-MSCs derived from human fore-
skin fibroblast angiogenesis in critical-sized calvarial rat
defects [85]. DMOG enhanced the expression of angiogenic
factors (hypoxia-inducible factor 1-α (HIF-1α) and VEGF)
through PI3K/Akt intracellular pathway activation, with
improved bone formation.

The osteogenic potential of iPSCs-MSCs in combination
with different scaffolds was investigated in several studies
[55, 86–90]. The subcutaneous implantation of osteoin-
duced episomal-iPSCs (generated using an episomal
vector) derived from BM stromal cells and retro-iPSCs
(generated using a retroviral vector) derived from DF cul-
tured on decellularized bone scaffold in SCID mice for 12
weeks revealed high mineral content in the episomal-iPSCs
as compared to retro-iPSCs [86]. On the other hand,
retro-iPSCs displayed the formation of a uniform bone-
like matrix with embedded cells, while episomal-iPSCs
exhibited areas of dystrophic calcification [86]. The osteo-
genetic potential of human fibroblast-derived iPSCs was
evaluated in vitro and in vivo on synthetic polymer polyca-
rolactone (PCL) scaffold or PCL scaffold functionalized
with natural polymer hyaluronan and ceramic tricalcium
phosphate ceramic poly (3-hexylthiophene (TCP-PHT))
[90]. The osteoinduced iPSCs revealed a significant increase
in ALP activity and calcium deposition on PHT scaffold
in vitro as well as ectopic bone formation in vivo in compar-
tion to PCL. Moreover, human fibroblast-derived iPSCs on
PCL nanofibers alone or combined with nano-HA showed
an increased expression of osteogenic genes (RUNX2, ALP,
COL1A1, and OCN) in both scaffolds, even though they were

Stem Cells International
expressed at a different time intervals, OCN was highly expressed in PCL-nano-HA in comparison to PCL scaffolds [89]. Similarly, the incorporation of short hydrophilic peptide H1 derived from connective tissue growth factor in a core silk fibroin (SF) combined with HA derived from poly (L-lactic acid-co-ε-caprolactone) (PLCL) resulted in increased proliferation and osteogenetic differentiation of iPSCs-MSCs derived from human fibroblasts [55].

The interaction between HA/TCP ceramic particles and iPSCs-MSCs was subsequently investigated in vivo [87, 88]. Rhesus macaques’ iPSC-derived mesodermal stromal-like cells mixed with HA/TCP demonstrated robust bone formation when implanted subcutaneously for eight weeks [87]. Furthermore, the osteogenic potential of iPSCs-MSCs from gingival fibroblasts, periodontal ligament cells, and human lung combined with HA/TCP was compared following implantation in SCID mice subcutaneously [88]. Although the three types of iPSCs-MSCs were able to form mineralized tissue, iPSCs-MSCs derived from periodontal ligament cells showed superior capability to form mature bone and connective tissue, which led to a controversial assumption that even after induction, iPSCs may retain epigenetic memory of their origin [91]. The combination of HA derived from PLCL with osteoinductive peptide H1 in a core SF and iPSCs-MSCs derived from human fibroblasts resulted in faster bone formation in vivo as compared to SF/PLCL following eight weeks of implantation in calvarial mouse defects [55].

Yet, although most of the aforementioned studies highlighted the osteogenic potential of iPSCs-MSCs in bone regeneration, Chijimatsu et al. reported that MSCs derived from iPSCs-neural crest cells failed to repair rat osteochondral knee defects in vivo despite their demonstrated chondrogenic and osteogenic capacity comparable to human BM-MSCs in vitro [92].

4.1.3. Osteogenic Differentiation Capability of iPSCs Compared to Other Types of Cells. The osteogenic differentiation ability of iPSCs-MSCs in comparison to MSCs was examined in a variety of studies [86, 93–95]. A study on iPSCs showed a delayed expression of osteogenic markers such as COL1A1 and bone sialoprotein (BSP) as well as weaker osteoblastic differentiation and mineral deposition, compared to human BM-MSCs in vitro [57]. Human fibroblast-derived iPSCs reprogrammed by mRNA (mRNA-iPSCs) or polycistrionic lentiviral vector (lenti-iPSCs) were compared to BM-MSCs [95]. Both methods of transduction produced cells that were similar in their morphology and surface antigen to BM-MSCs. Lenti-iPSCs revealed faster and more homogeneous calcium staining than mRNA-iPSCs. Although the expression of RUNX2, ALP, and OCN was stronger in BM-MSCs as compared to iPSCs-MSCs, the opposite was demonstrated for COL1A1 expression. Both iPSCs-MSCs showed osteogenic efficacy comparable to BM-MSCs. Similarly, osteoinduced mouse iPSCs-MSCs revealed the same surface antigen profile and higher osteogenic differentiation as BM-MSCs [93]. ALP, OSX, RUNX2, and OCN were intensely upregulated in osteoinduced iPSCs-MSCs aside from the formation of a mineralized matrix at day 14 of osteogenic induction. retro-iPSCs and episomal-iPSCs exhibited higher ALP gene expression than human ES cells [86]. Moreover, the osteogenic potential of iPSCs-MSCs derived from either human deciduous teeth or human DF was higher than that of osteoinduced SHED [94]. iPSCs-MSCs derived from equine fibroblast iPSCs were compared to MSCs derived from newborn foals’ umbilical cord blood (CB-MSCs) [96]. Von Kossa and alizarin red staining of iPSCs-MSCs showed early mineralization indicating early osteogenesis which was consistent with the results obtained from CB-MSCs.

Similarly, Ardeshiryalajimi et al. [97] compared the biological behavior and osteogenic differentiation potential of human iPSCs and adipose tissue (AT-MSCs), iPSCs confirmed high osteogenic differentiation potential and superior ALP activity and mineralization level. Notably, AT-MSCs expressed greater levels of RUNX2, while iPSCs expressed higher levels of OCN and osteonectin during differentiation which may be a result of their increased proliferation rate compared to AT-MSCs [97]. In vivo comparison of osteogenic potentials between adipose-derived stem cells (ASCs) and ASC-iPSCs loaded on nano-HA gelatin cryogel scaffolds revealed a superior osteogenic differentiation with enhanced osteogenic marker expression of COL1A1 and RUNX2 in the ASC-iPSCs group, proposing ASC-iPSCs as an alternative cell source in bone tissue engineering with a good differentiation ability [98].

On the other hand, the osteogenic potential of iPSCs derived from human skin fibroblasts was compared to iPSCs derived from BM-MSCs cultured on HA/TCP implanted subcutaneously in nude mice [99]. No differences in bone formation were revealed between iPSCs from different origins. In addition, the bone regeneration ability of adipose-derived stromal cells- (AS-) iPSCs was compared to human ES cells cultured on HA-coated PLGA scaffold with or without releasing BMP-2 in calvarial mouse defects [100]. Greater bone regeneration as well as upregulation of osteogenic markers was found in both AS-iPSCs and ES cells loaded on HA-PLGA releasing BMP-2 as compared to nonreleasing BMP-2 [100].

4.1.4. Factors to Improve the Osteogenic Potential of iPSCs (Figure 2). Exploring the therapeutic potential of iPSCs-MSCs in dental and nondental tissue regeneration entails the optimization of the factors that would enhance their osteogenic potential for future clinical applications. Genes, isoforms, laser application, suspension time of EBs, transduction method, natural antioxidant and anticancer products, and constituents of the scaffold material are factors that could enhance or affect the osteogenic potential of iPSCs. In order to attain iPSC osteogenic commitment, various inductive factors were applied including chemical inducers, biomolecules [101–103], growth factors [100], gene modification [104], two-dimensional culture environment [105], and modified three-dimensional scaffolds [100, 101, 106–108]. Tissue-nonspecific alkaline phosphatase (TNAP) was demonstrated to influence the osteogenic differentiation potential of iPSCs, where TNAP-positive cells isolated from human EBs derived from iPSCs and cultured in osteogenic media expressed high levels of OSX, RUNX2, COL1A1,
BSP, and OCN as well as generated mineralized nodules and revealed a significant expression of osteocyte marker genes, including sclerostin, neuropeptide Y, and reelin [109]. Similarly, extremely low-frequency electromagnetic field (ELF-EMF) (50 Hz and 1.5 mT) also significantly improved the osteogenic potential of iPSCs [110]. Resveratrol a natural polyphenol found largely in red grapes, nuts, pomegranates, and red wine [111] was also found to facilitate osteogenic differentiation of iPSCs, with increased osteogenic gene expression and mineralization content [112]. Growth factors such as recombinant human- (rh-) BMP-2 have been shown to positively modulate osteogenic transformation of iPSCs. Adding rh-BMP-2 to the osteogenic media improved the osteogenic potential of iPSCs derived from human AS through significant upregulation of osteogenic markers RUNX2 and OCN [100]. In vitro results showed that 3 wt/vol% nano-HA in chitosan/gelatin (CG) and miRNAs increased the expression of osteogenic-related genes [49, 50], formed bone-like tissue in vivo [49], and upregulated the OCN and OPN protein expression on day 21 after culturing [50].

Even though growth factors can endorse the osteogenic differentiation of iPSCs, their effects are limited due to their short half-lives and uncontrolled degradation. In contrast, gene modification of iPSC-derived cells can attain a long-term effect via retaining a relatively stable local concentration of these factors [113]. Certain genes such as nuclear matrix protein SATB2 have been transduced into iPSCs to promote osteodifferentiation [104]. An efficacious strategy for differentiating human iPSCs into osteoblasts involves using four small molecules including CHIR99021 (CHIR), cyclopamine (Cyc), smoothened agonist (SAG), and helioxanthin-derivative 4-(4-methoxyphenyl) pyrido [4′,3′:4,5] thieno [2,3-b] pyridine-2-carboxamide (TH) under chemically well-defined conditions [114]. Ex vivo gene therapy of SATB2-modified iPSCs increased the levels of calcium nodule formation, ALP activity, and osteogenic genes in vitro. Subsequent implantation of the transduced cells on silk scaffold encouraged bone regeneration in critical-sized calvarial defects [104]. On the contrary, iPSCs derived from tail-tip fibroblasts of Alox5 knockout mouse demonstrated significant downregulation of early and late osteogenic gene levels with significant upregulation of adipogenic markers. Still, loading Alox5-KO-iPSCs on collagen/chitosan/hydroxyapatite scaffolds induced significantly less new bone formation in rat cranial critical-sized defects as compared to wild-iPSCs [115].

Interestingly, iPSC origin demonstrated no effect on iPSC osteogenic potential. The osteogenic differentiation properties of human iPSCs derived from BM-MSCs and DFs demonstrated no marked differences in gene expression profiles as well as in the methylation profile. Moreover, the chondrogenic and osteogenic differentiation properties of iPSCs from different cells’ origin showed no significant differences, although a higher tendency was reported in DF-derived iPSCs [91]. Yet, different reprogramming methods could affect the osteogenic differentiation of iPSCs [86]. iPSCs derived from DF reprogrammed by retroviral vectors (retro-iPSCs) or Sendai virus (Sendai-iPSCs) cultured on decellularized bone scaffold in perfusion bioreactors demonstrated a new bone-like matrix with the highest cell density in Sendai-iPSCs, while retro-iPSCs showed poor osteogenic differentiation [86].

Human iPSCs derived from human embryonic kidney-Eβ were utilized to compare the osteoinductive properties of 3D nanofibrous scaffold of polyvinylidene fluoride (PVDF) with 2D scaffold [116] as well as to assess electrospun poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanofiber scaffold [117]. iPSCs revealed significantly high ALP activity, calcium content, and osteogenic-related genes after seeding on 3D PVDF [116] and PHBV scaffolds [117]. Moreover, OCN and OPN protein expressions were elevated on day 21 after cell seeding [116, 117]. Utilizing different ratios from nano-HA [49] or different miRNAs (miR-22 and miR-126) [50] in chitosan/gelatin (CG) scaffold or electrospun PCL nanofiber
scaffold, respectively, was also reported to affect the osteogenic differentiation of human iPSCs. Furthermore, incorporating basic fibroblast growth factor (bFGF) in PCL-PVDF scaffold [47] or polyphosphate (poly-P) in PCL/PLLA electrospun scaffolds [118] or graphene oxide (GO) in PVDF nanofibers [119] or platelet-rich plasma in PVDF/collagen nanofibrous scaffolds [120] significantly increased the survival rate of iPSCs and upregulated ALP activity, mineralization content, and expression of preosteoblast- and osteoblast-related genes in iPSCs loaded on PCL-PVDF (bFGF), PCL-PLLA (poly-P), PVDF-GO, or PVDF/Col/PRP scaffolds [47, 118–120]. A xeno-free nanofiber scaffold conjugated with vitronectin peptide upheld pluripotency and proliferation of seeded human iPSCs. Interestingly, this osteogenic culture system promoted direct osteodifferentiation of human iPSCs, as confirmed by the cellular morphology, ALP assay, and RT-PCR analysis combined with immunofluorescence results [101]. A recent report confirmed the osteogenic differentiation of human iPSCs into osteoblast-like cells with enhanced calcified nodule formation under the influence of retinoic acid in vitro and membranous bone tissue formation in vivo without scaffolds [103]. Under osteogenic conditions, human iPSCs cultured on PCL scaffolds confirmed osteogenesis by OPN detection using quantitative PCR and by western blotting. Further subcutaneous implantation in mice revealed marked calcium deposition and positive OCN immunostaining, with no signs of teratoma formation, following the osteogenic induction of human iPSCs [106]. The osteogenic potential of human iPSC-derived mesodermal progenitor cells (hiPSC-MP) on decellularized tissue matrices as scaffolding materials and human bone scaffolds in osteogenic medium under dynamic conditions was compared in perfusion bioreactors. Both scaffolds equally promoted cell viability and mineralized tissue formation [108]. Peptide-decorated 2D culture microenvironment developed through polydopamine (pDA) chemistry with subsequent carboxymethyl chitosan successfully promoted osteogenic differentiation of human iPSCs in vitro [105]. These results were supported by enhanced ALP activity, gene expression, and corresponding protein expression as well as the amount of calcium deposition [105]. Human iPSCs isolated from clinically discarded human gingival tissues were seeded on both sphere-shaped or rod-shaped nano-HA/CG scaffolds. Notably, the sphere-shaped nano-HA in HA/CG scaffolds greatly improved the osteogenic differentiation of human iPSCs as compared to rod-shaped. Consequently, human iPSCs and sphere-shaped nano-HA/CG composites generated a significant amount of bone in vivo [121].

Adenosine-induced differentiation of human iPSCs (Ad-iPSCs) loaded on poly (ethylene glycol) diacrylate-co-acryloyl 6-aminoacaproic acid (PEGDAA-co-A6ACA) macro-porous hydrogel into functioning osteoblast, in growth medium lacking any other osteoinductive factors, revealed progressive dense bone tissue formation. Furthermore, Ad-iPSCs implanted in critical-sized cranial bone defects in mice showed uniform hard tissue formation all over the cranial defect that was integrated with the adjacent bone without teratoma formation [102]. Moreover, ex vivo two-dimensional and three-dimensional cultures and mineralized gelatin methacrylate- (GelMA-) based matrices containing CaP mineral endorse the osteogenic differentiation of human iPSCs in osteoinductive factors free growth medium via the dissociation of Ca\(^{2+}\) and PO\(_4\)\(^{3-}\) ions in a permissive environment through various signaling pathways [107]. Similarly, ectopically implanted human iPSCs seeded on coral scaffolds in mice demonstrated the expression of bone-like structures through the release of osteoinductive factors including BMPs [122]. Paradoxically, the rapid disappearance of human iPSCs due to early cell death was associated with an increase in the osteogenic genes. To settle these conflicting trends, the authors investigated the paracrine effect of bioactive CM from human iPSCs. Interestingly, human iPSC CM promoted the osteogenic differentiation of human MSC osteogenic differentiation as well as upregulated the expression of BMP-2, BMP-4, and BMP-6 genes and enhanced extracellular matrix mineralization [122].

4.2. iPSCs and Salivary Gland Regeneration. iPSC therapeutic and regenerative potentials were exploited in the treatment of salivary glands’ diseases. In an in vivo study, iPSCs were utilized for treating salivary gland carcinoma induced in mice. Although iPSCs improved salivary gland function detected by a significant increase in the gene expression of α-amylase, the glands retained some malignant architecture including minor acinar, ductal, and vascular degenerative changes [123].

In an attempt to uncover the paracrine role of iPSCs in salivary gland regeneration, embryonic submandibular gland (SG) cells and mouse green fluorescent protein iPSCs (iSG) were cocultured. More developed epithelial structures were evident upon coculturing than in monoculture of embryonic SG cells. Upon morphological analysis of the regenerated tissues, iSG had a greater number of small acinar-like structures than that in SG cells. Additionally, analysis of differentiation markers among groups showed lower Sox2, e-Myc, and Nanog gene expression and higher Klf4 and Aqp5 gene expression in iSG with a remarkable regenerative capacity [124].

4.3. iPSCs and Periodontal Tissue Regeneration. iPSC differentiation into periodontal regenerative cells is affected by a variety of factors including cell source [125], culturing media [126], coculturing with inducing factors such as enamel matrix derivative (EMD) [127, 128], recombinant growth/differentiation factor-5 (GDF-5) [128, 129] or BMP-6 [130], the number of cellular passages [131], and type of scaffold used [130]. EBs generated from human gingival fibroblast and human neonatal skin fibroblast-derived iPSCs were induced into periodontal progenitor cells, which were then implanted on hydrogel scaffold subcutaneously in SCID rats. Owing to the cells’ inherent epigenetic memory, iPSCs derived from gingival fibroblasts showed a higher expression of periodontal cell markers in vitro, including BSP, cementum protein 1 and perioestin, and a formation of mineralized structure in vivo, with no teratoma formation observed with either cell types [125]. Neural crest cells derived from human skin fibroblast iPSCs cultured in combination with PDL cells’ extracellular matrix showed a higher proliferation rate and a stronger expression of periodontal cell markers, including COL1A1, fibrillin-1, OPG, and periostin, as compared to...
cells cultured with either fibronectin, laminin, or dermal fibroblast extracellular matrix [126].

Culturing EB derived from human foreskin iPSCs in combination with EMD gel promoted the expression of RUNX2, an early osteogenic marker, but inhibited the expression of OCN, a late osteogenic marker, and mineralization in vitro. To assess the effect of iPSCs and EMD on osteogenic differentiation and periodontal regeneration in vivo, EBs derived from mouse iPSCs were seeded on apatite-coated silk fibrin sheets with EMD before implantation in the periodontal fenestration defect rat model. Following iPSCs-EMD in vivo transplantation, OCN, RUNX2, and OSX expression was higher than those in the control group which was attributed to the ability of EMD to recruit a large number of osteogenic cells. Moreover, iPSCs-EMD were able to induce the formation of new bone almost filling the periodontal defect, promoted the formation of new cementum covering the surface of the root, and stimulated the formation of periodontal fibers perpendicular to the root surface proving that iPSCs-EMD can further be an efficient tool in periodontal regeneration [127].

The periodontal differentiation potential of iPSCs derived from human gingival fibroblasts and treated with growth differentiation factor- (GDF-) 5 was investigated at different passages [5, 10, 15, 20]. All iPSCs-GDF-5-treated passages revealed a high proliferative ability and attained fibroblast-like cell morphology, significant production of calcified nodules, and upregulated expression of bone-related gene (OCN and BSP), periodontal ligament-related gene (periostin and vimentin), and cementum-related genes (cementum attachment protein and cementum protein 1) as compared to their untreated controls [131]. Yet, the periodontal differentiation capability of iPSC-derived MSCs, obtained either from human gingival tissues or from peripheral blood mononuclear cells, was significantly increased after their treatment with recombinant human GDF-5 (rhGDF-5) [128, 129]. This was confirmed by the marked expression of periodontal tissue-related genes (OCN, periostin, and cementum attachment protein). On the contrary, BM-MSCs treated with rhGDF-5 demonstrated an insignificant expression of periostin and CAP, despite the high expression of OCN. Similar results were attained upon loading PKH67-labeled iPSCs-MSCs-rhGDF-5 on hyaluronic acid and subsequent implantation into the dorsal surface of 6-8-week-old male athymic nude mice. Moreover, after 4 weeks of culture with rhGDF-5, both BMSCs and iPSCs-MSCs showed noticeable mineralization with nodule formation [129]. Chitosan/gelatin/glycerol phosphate hydrogel 3D scaffold seeded with osteogenic-induced rat fibroblast-derived iPSCs and BMP-6 applied to periodontal defect created on the root surface of the maxillary first molar in rats significantly downregulated inflammatory cytokines interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-α), and IL-1β and promoted bone and periodontal tissue regeneration [130]. Additionally, human foreskin iPSC-derived MSCs, clotted with fibrinogen and thrombin implanted in periodontal fenestration defect in SCID rats, also revealed a significant increase in newly formed mineralized tissue area percentage [132].

Mesenchymal stromal cells derived from tail-tip fibroblast iPSCs (iPSCs-MCs) revealed immunomodulatory capabilities of the periodontal inflammatory destruction, which may offer a potential therapeutic modality for periodontal disease. In this context, a bacterial-induced periodontitis mouse model was established through local application of Porphyromonas gingivalis into the oral cavity and its systemic administration, while an acute inflammation model was created via subcutaneous implantation of heat-killed Porphyromonas gingivalis-impregnated sponge in rats. Rats were treated by systemic injection of iPSCs-MCs into the tail vein seven days following periodontitis establishment or by local iPSCs-MCs administration into the implantation site. iPSCs-MCs showed a significant reduction in inflammation and alveolar bone loss in the periodontitis rats’ model. Moreover, local or systemic iPSC treatment in the acute inflammation model showed a reduced expression of the proinflammatory cytokine CXCL1, while local iPSCs-MCs administration resulted in a significant reduction in the inflammatory score [133]. Similarly, periodontitis was induced around the maxillary first molar bilaterally in female rats by ligature and subsequent infection with Porphyromonas gingivalis. The rats were treated intravenously and topically with rat iPSCs-MSCs reprogrammed from rat embryonic fibroblasts and transduced with tumor necrosis factor alpha-stimulated gene-6 (TSG-6) (iPSCs-MSCs/TSG-6). A significant downregulated level of alveolar bone loss, a few number of TRAP-positive osteoclasts, and serum interleukin 1β (IL-1β) and tumor necrosis factor alpha (TNF-α) were demonstrated as compared to untreated rats [134].

4.4. iPSCs and Enamel Regeneration. Ameloblasts are crucial cell populations required for enamel formation. The ability of mouse iPSCs (miPSCs) to differentiate into ameloblast was investigated [135], where miPSCs cocultured with dental epithelial cells differentiated into ameloblasts, exhibiting epithelial cell-like morphology in addition to expressing ameloblastic markers (ameloblastin and enamelin) and epithelial markers (p63 and cytokeratin- (CK-)14), suggesting an epithelial-mesenchymal interaction role in tooth development. Similarly, miPSCs differentiated into ameloblast-like cells under feeder-free conditions, using cultured epithelial rests of Malassez (ERM) cell CM and gelatin-coated dishes [136]. The differentiated ameloblast-like cells demonstrated an increase in expression of CK-14, amelogenin, and ameloblastin in comparison to miPSCs cocultured with ERM cells. The levels of amelogenin expression in ameloblast-like cells were significantly higher than those in miPSCs cocultured with ERM cells throughout the experiment, while ameloblastin increased significantly on day 14. Moreover, the addition of neurotrophin-4 to miPSCs under serum-free culture conditions during EB formation leads to their differentiation into dental epithelial-like cells with the upregulation of epithelial and ameloblastic markers [137]. These studies highlighted the potential differentiation ability of iPSCs into ameloblasts confirming that iPSCs could be a new cell source for enamel regeneration.
4.5. iPSCs and Dentin Pulp Complex Regeneration. The generation of odontoblast cells from iPSCs could open new opportunities for treating dentinal and/or pulpal damage. Epithelial-mesenchymal interactions are required for differentiating iPSCs into odontoblasts. Herein, the study described the “hanging drop” technique for differentiating miPSCs into odontoblast-like cells exploiting such an interaction. iPSCs were differentiated into EBs and then cultured on a collagen scaffold (CS) in combination with BMP-4 (CS/BMP-4). The generated cells intensely expressed mature odontoblast markers, dentin sialoprotein (DSP), and dentin matrix protein-1 (DMP-1) and presented physiological as well as functional features of odontoblasts [138]. Moreover, in an in vitro model, matrix metalloproteinase- (MMP-) 3 small interfering RNA was transfected into odontoblast-like cells derived from iPSCs. Strikingly, treatment with inorganic polyphosphate induced MMP-3 that physiologically accelerated both proliferation and differentiation of odontoblast-like cells, thereby hypothesized to provide some protection to the cells against the detrimental effects of inflammation and pulp capping materials. Additionally, DSP and DMP-1 mRNA expressions were upregulated [139].

Under modified culture protocols, miPSCs were differentiated into neural crest-like cells (NCLCs) that could further differentiate into iPSC-derived dental mesenchymal cells (DMC) including odontoblast progenitor cells. Results showed that iPSC-derived NCLCs expressed NC markers as demonstrated by immunocytochemistry, flow cytometry, and RT-PCR. Furthermore, NCLCs expressed MSC markers, in addition to Pax9 and DSP, proving their capacity to differentiate into dental mesenchyme, when cultured with dental epithelium [140]. Interestingly, gene transfection of Pax9 and BMP-4 into iPSC-derived NCLCs promoted their differentiation into odontoblast-like cells, thus prompting signaling modulation of DMP-1 and DSP expression, associated with odontoblastic differentiation of miPSCs [141]. In another study, dental pulp stem cells (DSPCs) were reprogrammed into iPSCs; then, the cells were seeded on dentin discs with PLLA scaffolds and implanted subcutaneously in mice. Amazingly, iPSCs generated a pulp-like tissue having tubular dentin, while in vitro, iPSCs maintained the odontogenic and mineralization potential after long-term expansion opposite to DSPCs [142].

4.6. iPSCs and Whole Tooth Regeneration. In addition to ameloblastic and odontoblastic differentiation potential of iPSCs, the capability of iPSCs in whole tooth regeneration was investigated [143–145]. miPSCs which clearly express odontogenic and osteogenic genes following their induction were implanted combined with epithelial and mesenchymal cells in a tooth germ model and transplanted into subrenal mouse capsule [145]. After four weeks of implantation, the formation of bone, dental pulp-like, and irregular tooth-like structures was demonstrated. Additionally, OPN was expressed in the apical region of the tooth-like structure. Notably, implantation of miPSCs alone failed to form dental or bone-like structures in contrast to its combined implantation with epithelial and mesenchymal cells.

Human iPSCs, derived from urine cells, were differentiated into epithelial sheets and cocultured with mouse dental mesenchyme, demonstrating an ability to form tooth-like structures such as enamel organ, enamel space, dentin, and dental pulp with physical and chemical properties similar to human teeth [143]. Further, through specific human antigen expression, it was revealed that iPSC epithelial sheets differentiated into ameloblast, while dental mesenchymal cells gave rise to the rest of the formed dental tissues. Interestingly, mouse dental mesenchymal cells alone formed bone-like tissue rather than tooth-like structure. Furthermore, miPSCs cultured in ameloblast serum-free CM supplemented with BMP-4 displayed the ability to form ameloblast-like and odontoblast-like cells [144]. In addition, ameloblast serum-free CM increased the gene and protein expression of enamelin, ameloblastin, and CK-14, as well as phosphorylated Smad1/5, p38 MAPK, and ERK1/2 MAPK in miPSCs as compared with miPSCs cultured in epithelial cell medium for 14 days. Smad1/5 signaling transduction regulates the ameloblastic differentiation of miPSCs induced by ameloblast serum-free CM as the inhibition of Smad1/5 phosphorylation significantly reversed the increased the previously mentioned expression profile [146]. These results raise the possibility of iPSCs’ use in whole tooth engineering opening a new gateway for biological tooth replacement.

5. Challenges Facing iPSCs’ Human Clinical Applications

One of the major drawbacks that could hinder iPSCs’ clinical application is their reported chromosomal instability and the underlying risk of tumor formation, which constitutes a substantial health hazard [12, 147]. Undifferentiated iPSCs’ pluripotency and their ability to differentiate into tissues derived from the three germ layers are an incentive to teratoma formation, which is used as an assay to test their pluripotency [33, 148]. Moreover, iPSCs express several oncogenic genes [149]. Owing to iPSCs’ unique properties, the generated tumor properties and origin are highly unpredictable and vary with the transplanted cell number as well as the utilized cell line [150]. In addition to their innate tendency for teratoma formation, the method of gene transduction can also increase the risk of tumorigenesis particularly due to the use of viruses that integrate their genome into the reprogrammed cells, as previously discussed. Currently, several attempts are carried out to overcome this through the use of nonviral vectors [25, 26] but are hindered by their lower transfection efficacy, especially following iPSC passaging.

Luckily, utilizing terminally differentiated iPSCs prior to implantation in addition to using nonviral vectors can help reduce risk of tumor formation [151]. Moreover, iPSCs can be reprogrammed via Oct3/4, Sox2, and Klf4, while omitting c-Myc which is a potent oncogene [14, 15, 152]. However, even following iPSC terminal differentiation, some cells may escape differentiation. Residual undifferentiated or partially differentiated iPSCs in the cellular transplants may cause teratoma formation upon implantation in the recipient tissues [153, 154]. Furthermore, iPSCs could retain epigenetic memory, which may affect their subsequent
differentiation and direct them into lineages related to their parent cells [155, 156].

Another limitation associated with most current stem-/progenitor cell isolation and expansion protocols lies in the utilization of xenogeneic-derived products in iPSC protocols. iPSCs are usually cultured on xenogeneic feeder cells that maintain the cells in an undifferentiated state without affecting their pluripotency [157], as well as fetal bovine serum that represents an important culture medium constituent [151, 158]. Using xenogeneic products in clinical trials could elicit an immunogenic reaction, carry a risk of disease transmission [151, 158], and affect reproductibility, as the exact composition of bovine serum varies greatly [159]. An additional problem creating an obstacle for the clinical application of iPSCs is the reduced generation efficacy [23], where iPSC generation efficiency using fibroblasts is extremely low. Even though generation efficiency is 4 to 10 times greater using dental pulp stem cells than fibroblasts, it is still relatively low for application in regenerative medicine [151].

6. Short- and Long-Term Perspectives of iPSC-Mediated Tissue Regeneration

Despite that iPSCs have shown promising results in regenerative medicine, a number of issues are yet to be resolved to allow their translation into clinical application while minimizing their potential side effects. Coculturing iPSCs with cells and growth factors could provide a promising solution to overcome tissue engineering challenges through mimicking in vivo conditions to optimize tissue regeneration results. Upon coculturing iPSCs-MSCs with iPSCs-macrophages committed to osteoblastogenesis and osteoclastogenesis, an OPG/RANKL milieu could be provided [80]. Similarly, coculturing iPSCs with dental epithelial and mesenchymal cells can reproduce epithelial-mesenchymal interaction signals orchestrating the process of tooth development. So far, securing an epithelial-mesenchymal interaction represents a great obstacle in whole tooth regeneration [135, 143]. Epithelial-mesenchymal interaction signals thereby remain to be the key towards inducing the differentiation of iPSCs into ameloblasts and other dental cells, which is the first step in whole tooth regeneration. Moreover, defining the best combination of iPSCs, signaling molecules such as growth factors, and scaffold biomaterials and determining the ideal architectural design of the scaffold 2D or 3D, sphere- or rod-shaped, remain crucial for various applications of iPSCs in dental and parodontal tissue regeneration.

Transduction of repaired, edited, and/or modified genes in iPSCs could be a beneficial tool for treating various disorders. In this context, repairing RUNX2 gene mutation in iPSCs derived from cleidocranial dysostosis patients [52] as well as transducing nuclear matrix protein SATB2 [104] and Alox5 gene into iPSCs promoted osteo differentiation [115]. Besides, Pax9 and BMP-4 gene transfection into iPSC-derived NCLCs promoted odontoblast-like cell differentiation [141] and attained a long-term effect of these factors rather than the short-term effect acquired following their local application [113].

iPSCs’ extracellular vesicles, containing protein, mRNA, and miRNA, can further be used in regenerative medicine, seizing the paracrine effect of iPSCs while avoiding the possible risk of tumorigenesis associated with iPSC-based therapy [160]. The paracrine role of iPSCs in salivary gland regeneration has been proven upon coculturing embryonic submandibular gland cells and mouse iPSCs [124]. Besides, human iPSC CM promoted the osteogenic differentiation of human MSCs [122]. Usage of iPSC-derived secretome for tissue regeneration merits further research such as determining the active genes and growth factors expressed in CM from iPSCs.

Defining the optimum and the most accessible cell source to attain iPSCs should be investigated in the future to maximize their differentiation potential as well as their generation efficacy. iPSCs proved to retain their epigenetic memory, which may affect their subsequent differentiation [155, 156]. For example, iPSCs derived from gingival fibroblasts showed a higher expression of periodontal cell markers in vitro [125]. This could be beneficial in using particular cell sources for specific tissue regeneration, but it hinders the wide range of cells that could be derived from iPSCs. Despite that gingival fibroblasts and urine cells could be considered an easy source for attaining iPSCs, the generation efficiency of iPSCs using fibroblasts is extremely low [151].

A better control of the differentiation potential of iPSCs could be achieved by defining the suspension time of EB, since iPSCs-MSCs obtained at early EB suspension time possessed a more stem cell phenotype while those cells obtained later acquired a more differentiated phenotype [68], and by controlling and optimizing the reprogramming method where the highest cell density was attained in Sendai-iPSCs, while retro-iPSCs showed poor osteogenic differentiation [86].

Finally, next-generation sequencing could be alternatively used to assess the pluripotency potential, following iPSC generation instead of the complicated current techniques including teratoma formation and in vitro embryoid body (EB) generation [32].

7. Conclusion

iPSCs represent an autologous cell source, derived from the patient’s own tissue, with no risk of immune reaction [161–163]. They have higher proliferative rates than adult stem cells and can be acquired via noninvasive methods [161], all properties that are highly desirable in regenerative medicine. Despite challenges associated with iPSCs’ clinical use, their potential impact on medical applications still warrants further research. Carrying the application of iPSCs for tissue regeneration into humans entails strict abiding to the conduct of good manufacturing practice (GMP), as well as properly selecting cell source, culturing media, and vectors for gene transduction and excluding any xenogeneic-derived products from iPSC generation protocols. Recently, iPSCs have been successfully generated using a protocol compliant with GMP from hematopoietic stem cells from peripheral blood [164]. Furthermore, iPSCs were successfully maintained undifferentiated in xenogeneic-free culture medium.
and were subsequently differentiated into MSCs and osteogenic cells. Positive results were also attained following implantation in rats’ calvarial defects [165] which paves the way for carrying iPSCs into clinical trials. Initial reports documented that the risk of teratoma formation associated with iPSC transplantation could be inhibited by pretreatment with resveratrol [112] or by irradiation of 2 Gray (Gy) prior to transplantation [43]. Finally, iPSCs’ extracellular vesicles and secretomes, containing protein, mRNA, and miRNA, can alternatively be used, exploiting the paracrine effect of iPSCs while avoiding the risk of tumorigenesis associated with iPSC-based therapy [160].

It can thus be concluded that even though iPSCs hold a tremendously unexplored potential in the field of regenerative medicine, bone and dental tissue engineering, therapeutic application in bone disorders, gene therapy, and personalized medicine, a number of obstacles must be alleviated to attain their clinical applications. iPSCs still warrant further research focusing on achieving a safe, efficient reprogramming and attaining significant expansion while evading postimplantation tumor risks. Unleashing the full capabilities of iPSCs holds a promise of offering remedies to several genetic disorders in addition to their potential application in bone and dental tissue regeneration.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ALP          | Alkaline phosphatase |
| ASC-iPSCs    | Adipose-derived induced pluripotent stem cells |
| AT-MSCs      | Human adipose tissue |
| bFGF         | Basic fibroblast growth factor |
| BM-MSCs      | Bone marrow mesenchymal stem cells |
| BMP          | Bone morphogenetic protein |
| BMSC         | Bone marrow stromal cells |
| CA           | Cytomegalovirus enhancer/b-actin |
| CCD          | Cleidocranial dysostosis |
| CCHS         | Collagen/chitosan/hydroxyapatite scaffolds |
| CM           | Conditioned media |
| CMC          | Carboxymethyl chitosan |
| Col2.3GFP    | 2.3 kb type I collagen promoter-driven green fluorescent protein |
| CPC          | Calcium phosphate cement |
| DFs          | Dermal fibroblasts |
| DPI-VTK      | Dpiyalswsgma-Vthlnqisqsy |
| EBs          | Embryoid bodies |
| EF           | Embryonic fibroblasts |
| ELF-EMF      | Extremely low-frequency electromagnetic field |
| EMD          | Enamel matrix derivatives |
| ES           | Embryonic stem |
| G/C/GP       | Chitosan/gelatin/glycerol phosphate |
| GDF-5        | Growth/differentiation factor-5 |
| GO           | Graphene oxide |
| HA/Col/CTS   | Hydroxyapatite/collagen/chitosan |
| HA/TCP       | Hydroxyapatite/tricalcium phosphate |
| HA           | Hydroxyapatite |
| HCG          | Nanohydroxyapatite/chitosan/gelatin |
| HEK          | Human embryonic kidney |
| hiPSCs       | Human induced pluripotent stem cells |
| HUVECs       | Human umbilical vein endothelial cells |
| iPSCs        | Induced pluripotent stem cells |
| iPSCs-NC-PDL | iPSCs induced into neural crest- (NC-) like cells |
| iPSCs-NC     | p75 neurotrophin receptor-positive cells were cultured on extracellular matrix (ECM) produced by human PDL |
| MSCs         | Mesenchymal stem cells |
| NCLCs        | Neural crest-like cells |
| nHA/CG scaffolds | Nanohydroxyapatite/chitosan/gelatin scaffolds |
| nHA          | Nanohydroxyapatite |
| OM           | Osteogenic media |
| PCL          | Polycaprolactone |
| PCL-PPLA     | Polycaprolactone-poly-L-lactic acid |
| PCL-PVDF     | Polycaprolactone-polyvinylidene fluoride |
| pDA          | Polydopamine |
| PBMC         | Peripheral blood mononuclear cell |
| PDL          | Periodontal ligaments |
| PEG          | Polyethylene glycol |
| PES          | Polyethersulfone |
| PHT          | Polymer hyaluronan and ceramic tricalcium phosphate ceramic particles |
| PL:          | Poly-L-lactic acid |
| PLCL         | Poly (L-lactic acid-co-ε-caprolactone) |
| PLGA/PLLA    | Poly lactic-co-glyceric acid/poly L-lactic acid |
| Poly-P       | Polyphosphate |
| PVDF         | Polyvinylidene fluoride |
| PVDF/Col/PRP | Polyvinylidene fluoride/collagen/platelet-rich plasma |
| RGD          | Arg-Gly-Asp |
| RUNX2        | Runt-related transcription factor 2 |
| SHED         | Human exfoliated deciduous teeth |
| TGF-β        | Transforming growth factor-beta |
| TNP          | Tissue-nonspecific alkaline phosphatase |
| TSG-6        | Tumor necrosis factor alpha-stimulated gene-6 |

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] M. J. Evans and M. H. Kaufman, "Establishment in culture of pluripotential cells from mouse embryos," Nature, vol. 292, no. 5819, pp. 154–156, 1981.

[2] L. Gepstein, "Derivation and potential applications of human embryonic stem cells," Circulation Research, vol. 91, no. 10, pp. 866–876, 2002.

[3] G. R. Martin, "Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 12, pp. 7634–7638, 1981.
[4] J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., “Embryonic cell line derived from human blastocyst,” Science, vol. 282, no. 5391, pp. 1145–1147, 1998.

[5] Y.-C. Chen, K.-L. Tsai, C.-W. Hung et al., "Induced pluripotent stem cells and regenerative medicine," Journal of Clinical Gerontology and Geriatrics, vol. 2, no. 1, article S2210833510000389, pp. 1–6, 2011.

[6] K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.

[7] E. E. Morales and R. A. Wingert, “Renal stem cell reprogramming: prospects in regenerative medicine,” World Journal of Stem Cells, vol. 6, no. 4, pp. 458–466, 2014.

[8] S. Zhu, W. Li, H. Zhou et al., “Reprogramming of human primary somatic cells by OCT4 and chemical compounds,” Cell Stem Cell, vol. 7, no. 6, pp. 651–655, 2010.

[9] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.

[10] B. Ebrahimi, “Reprogramming of adult stem/progenitor cells into iPSCs without reprogramming factors,” Journal of Medical Hypotheses and Ideas, vol. 9, no. 2, pp. 99–103, 2015.

[11] E. Kiskinis and K. Eggan, “Progress toward the clinical application of patient-specific pluripotent stem cells,” The Journal of Clinical Investigation, vol. 120, no. 1, pp. 51–59, 2010.

[12] S. Raab, M. Klingenstein, S. Liebau, and L. Linta, “A comparative view on human somatic cell sources for iPSC generation,” Stem Cells International, vol. 2014, Article ID 768391, 12 pages, 2014.

[13] N. Wada, B. Wang, N. H. Lin, A. L. Laslett, S. Gronthos, and P. M. Bartold, “Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts,” Journal of Periodontal Research, vol. 46, no. 4, pp. 438–447, 2011.

[14] H. Egusa, K. Okita, H. Kayashima et al., “Gingival fibroblasts as a promising source of induced pluripotent stem cells,” PLoS One, vol. 5, no. 9, article e12743, 2010.

[15] Y. Nomura, M. Ishikawa, Y. Yashiro et al., “Human periodontal ligament fibroblasts are the optimal cell source for induced pluripotent stem cells,” Histochemistry and Cell Biology, vol. 137, no. 6, pp. 719–732, 2012.

[16] K. Otsu, M. Kumakami-Sakano, N. Fujisawa et al., “Stem cell sources for tooth regeneration: current status and future prospects,” Frontiers in Physiology, vol. 5, p. 36, 2014.

[17] N. Tamaoki, K. Takahashi, T. Tanaka et al., “Dental pulp cells for induced pluripotent stem cell banking,” Journal of Dental Research, vol. 89, no. 8, pp. 773–778, 2010.

[18] X. Yan, H. Qin, C. Qu, R. S. Tuan, S. Shi, and G. T. J. Huang, “iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin,” Stem Cells and Development, vol. 19, no. 4, pp. 469–480, 2010.

[19] P. C. B. Beltrão-Braga, G. C. Pignatari, P. C. Maiorka et al., “Feeder-free derivation of induced pluripotent stem cells from human immature dental pulp stem cells,” Cell Transplantation, vol. 20, no. 11–12, pp. 1707–1719, 2011.

[20] K. Okita, M. Nakagawa, H. Hyenjong, T. Ichisaka, and S. Yamanaka, "Generation of mouse induced pluripotent stem cells without viral vectors," Science, vol. 322, no. 5903, pp. 949–953, 2008.

[21] W. Deng, “Induced pluripotent stem cells: paths to new medicines. A catalyst for disease modeling, drug discovery and regenerative therapy,” EMBO Reports, vol. 11, no. 3, pp. 161–165, 2010.

[22] S. P. Medvedev, A. I. Shevchenko, and S. M. Zakian, “Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine,” Acta Naturae, vol. 2, no. 2, pp. 18–27, 2010.

[23] S. Romanazzo, S. Nemec, and I. Roohani, “iPSC bioprinting: where are we at?,” Materials, vol. 12, no. 15, article 2453, 2019.

[24] K. Tashiro, M. Inamura, K. Kawabata et al., “Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenosinergic transduction,” Stem Cells, vol. 27, no. 8, pp. 1802–1811, 2009.

[25] D. Kim, C.-H. Kim, J.-I. Moon et al., “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins,” Cell Stem Cell, vol. 4, no. 6, pp. 472–476, 2009.

[26] L. Warren, P. D. Manos, T. Ahfeldt et al., “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA,” Cell Stem Cell, vol. 7, no. 5, pp. 618–630, 2010.

[27] F. Anokye-Danso, C. M. Trivedi, D. Juhr et al., “Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency,” Cell Stem Cell, vol. 8, no. 4, pp. 376–388, 2011.

[28] N. Miyoshi, H. Ishii, H. Nagano et al., “Reprogramming of mouse and human cells to pluripotency using mature microRNAs,” Cell Stem Cell, vol. 8, no. 6, pp. 633–638, 2011.

[29] B. Saha, M. P. Borgohain, C. Dey, and R. P. Thummer, “iPS cell generation: current and future challenges,” Annals of Stem Cell Research & Therapy, vol. 1, no. 2, p. 1007, 2018.

[30] N. Malik and M. S. Rao, “A review of the methods for human iPSC derivation,” Methods in Molecular Biology, vol. 997, pp. 23–33, 2013.

[31] P. Czerwinska, S. Mazurek, I. Kołodziejczak, and M. Wiznerowicz, “Gene delivery methods and genome editing of human pluripotent stem cells,” Reports of Practical Oncology and Radiotherapy, vol. 24, no. 2, pp. 180–187, 2019.

[32] R. Jaenisch and R. Young, “Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming,” Cell, vol. 132, no. 4, pp. 567–582, 2008.

[33] S. D. Sheridan, V. Surampudi, and R. R. Rao, “Analysis of embryoid bodies derived from human induced pluripotent stem cells as a means to assess pluripotency,” Stem Cells International, vol. 2012, Article ID 738910, 9 pages, 2012.

[34] H. Kurosawa, “Methods for inducing embryoid body formation: in vitro differentiation system of embryonic stem cells,” Journal of Bioscience and Bioengineering, vol. 103, no. 5, pp. 389–398, 2007.

[35] G. Pettinato, X. Wen, and N. Zhang, “Formation of well-defined embryoid bodies from dissociated human induced pluripotent stem cells using microfabricated cell-repellent microwell arrays,” Scientific Reports, vol. 4, no. 1, article 7402, 2014.

[36] J. Itskovitz-Eldor, M. Shuldiner, D. Karsenti et al., “Differentiation of human embryonic stem cells into embryoid bodies
comprising the three embryonic germ layers,” *Molecular Medicine*, vol. 6, no. 2, pp. 88–95, 2000.

[37] A. J. Joannides, C. Fiore-Hériché, A. A. Battersby et al., “A scaleable and defined system for generating neural stem cells from human embryonic stem cells,” *Stem Cells*, vol. 25, no. 3, pp. 731–737, 2007.

[38] J. C. Mohr, J. Zhang, S. M. Azarin et al., “The microwell control of embryoid body size in order to regulate cardiac differentiation of human embryonic stem cells,” *Biomaterials*, vol. 31, no. 7, pp. 1885–1893, 2010.

[39] B. Valamehr, S. J. Jonas, J. Polleux et al., “Hydrophobic surfaces for enhanced differentiation of embryonic stem cell-derived embryoid bodies,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 38, pp. 14459–14464, 2008.

[40] A. Sakkas, F. Wilde, M. Heufelder, K. Winter, and A. Schramm, "Autogenous bone grafts in oral implantology—is it still a "gold standard"? A consecutive review of 279 patients with 456 clinical procedures," *International Journal of Implant Dentistry*, vol. 3, no. 1, p. 23, 2017.

[41] Z. Sheikh, N. Hamdan, Y. Ikeda, M. Grynpas, B. Ganss, and M. Glogauer, "Natural graft tissues and synthetic biomaterials for periodontal and alveolar bone reconstructive applications: a review," *Biomaterials Research*, vol. 21, no. 1, p. 9, 2017.

[42] D. Rana, S. Kumar, T. J. Webster, and M. Ramalingam, "Impact of induced pluripotent stem cells in bone repair and regeneration," *Current Osteoporosis Reports*, vol. 17, no. 4, pp. 226–234, 2019.

[43] T. Hayashi, H. Misawa, H. Nakahara et al., “Transplantation of osteogenically differentiated mouse iPS cells for bone repair,” *Cell Transplantation*, vol. 21, no. 2-3, pp. 591–600, 2012.

[44] S. T. Kumaran, K. V. Arun, S. Sudarsan, A. Talwar, and N. Srinivasan, "Osteoblast response to commercially available demineralized bone matrices—an in-vitro study,” *Indian Journal of Dental Research*, vol. 21, no. 1, pp. 3–9, 2010.

[45] N. Quarto, S. Li, A. Renda, and M. T. Longaker, "Exogenous activation of BMP-2 signaling overcomes TGFβ-Mediated inhibition of osteogenesis in Marfan embryonic stem cells and Marfan patient-specific induced pluripotent stem cells,” *Stem Cells*, vol. 30, no. 12, pp. 2709–2719, 2012.

[46] N. I. zur Nieden, G. Kempka, and H. J. Ahr, “In vitro differentiation of embryonic stem cells into mineralized osteoblasts,” *Differentiation*, vol. 71, no. 1, pp. 18–27, 2003.

[47] M. F. Abazari, F. Soleimanifar, S. E. Enderami et al., "Incorporated-bFGF polycaprolactone/polyvinylidene fluoride nanocomposite scaffold promotes human induced pluripotent stem cells osteogenic differentiation,” *Journal of Cellular Biochemistry*, vol. 120, no. 10, pp. 16750–16759, 2019.

[48] A. Ardeshirylajimi, S. Hosseinkhani, K. Parivar, P. Yaghmaie, and M. Soleimani, "Nanofiber-based polyethersulfone scaffold and efficient differentiation of human induced pluripotent stem cells into osteoblastic lineage,” *Molecular Biology Reports*, vol. 40, no. 7, pp. 4287–4294, 2013.

[49] J. Ji, X. Tong, X. Huang, J. Zhang, H. Qin, and Q. Hu, “Patient-derived human induced pluripotent stem cells from gingival fibroblasts composites with defined nanohydroxyapatite/chitosan/gelatin porous scaffolds as potential bone graft substitutes,” *Stem Cells Translational Medicine*, vol. 5, no. 1, pp. 95–105, 2016.

[50] A. Tahmasebi, S. E. Enderami, E. Saburi et al., “Micro-RNA-incorporated electrospun nanofibers improve osteogenic differentiation of human-induced pluripotent stem cells,” *Journal of Biomedical Materials Research Part A*, vol. 108, no. 2, pp. 377–386, 2019.

[51] M.-S. Ma, V. Kannan, A. E. de Vries et al., “Characterization and comparison of osteoblasts derived from mouse embryonic stem cells and induced pluripotent stem cells,” *Journal of Bone and Mineral Metabolism*, vol. 35, no. 1, pp. 21–30, 2017.

[52] A. Saito, A. Ooki, T. Nakamura et al., “Targeted reversion of induced pluripotent stem cells from patients with human cleidocranial dysplasia improves bone regeneration in a rat calvarial bone defect model,” *Stem Cell Research & Therapy*, vol. 9, no. 1, p. 12, 2018.

[53] A. Ardeshirylajimi, P. Dinarvand, E. SeyediJafari, L. Langrudi, F. Jamshidi Adegani, and M. Soleimani, “Enhanced reconstruction of rat calvarial defects achieved by plasma-treated electrospun scaffolds and induced pluripotent stem cells,” *Cell and Tissue Research*, vol. 354, no. 3, pp. 849–860, 2013.

[54] H. Zhu, T. Kimura, S. Swami, and J. Y. Wu, “Pluripotent stem cells as a source of osteoblasts for bone tissue regeneration,” *Biomaterials*, vol. 196, pp. 31–45, 2019.

[55] R. Xu, Z. Zhang, M. S. Toftdal et al., “Synchronous delivery of hydroxyapatite and connective tissue growth factor derived osteoinductive peptide enhanced osteogenesis,” *Journal of Controlled Release*, vol. 301, pp. 129–139, 2019.

[56] K. Hayashi, H. Ochiai-Shino, T. Shiga et al., “Transplantation of human-induced pluripotent stem cells carried by self-assembling peptide nanofiber hydrogel improves bone regeneration in rat calvarial bone defects,” *BJD Open*, vol. 2, no. 1, article 15007, 2016.

[57] J.-Y. Ko, S. Park, and G.-I. Im, “Osteogenesis from human induced pluripotent stem cells: an in vitro and in vivo comparison with mesenchymal stem cells,” *Stem Cells and Development*, vol. 23, no. 15, pp. 1788–1797, 2014.

[58] T.-J. Lee, J. Jang, S. Kang et al., “Mesenchymal stem cell-conditioned medium enhances osteogenic and chondrogenic differentiation of human embryonic stem cells and human induced pluripotent stem cells by mesodermal lineage induction,” *Tissue Engineering Part A*, vol. 20, no. 7-8, pp. 1306–1313, 2014.

[59] S. Zhong, X. He, Y. Li, and X. Lou, “Conditioned medium enhances osteogenic differentiation of induced pluripotent stem cell-derived mesenchymal stem cells,” *Tissue Engineering and Regenerative Medicine*, vol. 16, no. 2, pp. 141–150, 2019.

[60] F. Li, S. Bronson, and C. Niyyibizi, “Derivation of murine induced pluripotent stem cells (iPS) and assessment of their differentiation toward osteogenic lineage,” *Journal of Cellular Biochemistry*, vol. 109, no. 4, pp. 643–652, 2010.

[61] F. Li and C. Niyyibizi, “Cells derived from murine induced pluripotent stem cells (iPSC) by treatment with members of TGF-beta family give rise to osteoblasts differentiation and form bone in vivo,” *BMC Cell Biology*, vol. 13, no. 1, p. 35, 2012.

[62] P. Wang, T. Ma, D. Guo et al., “Metformin induces osteoblastic differentiation of human induced pluripotent stem cell-derived mesenchymal stem cells,” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 12, no. 2, pp. 437–446, 2018.
[63] W. Chen, X. Liu, Q. Chen et al., “Angiogenic and osteogenic regeneration in rats via calcium phosphate scaffold and endothelial cell co-culture with human bone marrow mesenchymal stem cells (MSCs), human umbilical cord MSCs, human induced pluripotent stem cell-derived MSCs and human embry,” Journal of Tissue Engineering and Regenerative Medicine, vol. 12, no. 1, pp. 191–203, 2018.

[64] X. Liu, W. Chen, C. Zhang et al., “Co-seeding human endothelial cells with human-induced pluripotent stem cell-derived mesenchymal stem cells on calcium phosphate scaffold enhances osteogenesis and vascularization in rats,” Tissue Engineering Part A, vol. 23, no. 11-12, pp. 546–555, 2017.

[65] C. Zhang, K. Hu, X. Liu et al., “Novel hiPSC-based tri-culture for pre-vascularization of calcium phosphate scaffold to enhance bone and vessel formation,” Materials Science & Engineering C, Materials for Biological Applications, vol. 79, pp. 296–304, 2017.

[66] J. Liu, W. Chen, Z. Zhao, and H. H. K. Xu, “Reprogramming of mesenchymal stem cells derived from iPSCs seeded on bio-functionalized calcium phosphate scaffold for bone engineering,” Biomaterials, vol. 34, no. 32, pp. 7862–7872, 2013.

[67] J. Liu, W. Chen, Z. Zhao, and H. H. K. Xu, “Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement,” Acta Biomaterialia, vol. 10, no. 12, pp. 5128–5138, 2014.

[68] D. Sheyn, S. Ben-David, G. Shapiro et al., “Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects,” Stem Cells Translational Medicine, vol. 5, no. 11, pp. 1447–1460, 2016.

[69] P. Wang, Y. Song, M. D. Weir et al., “A self-setting iPMSC-alginate-calcium phosphate paste for bone tissue engineering,” Dental Materials, vol. 32, no. 2, pp. 252–263, 2016.

[70] Q. Wu, B. Yang, C. Cao, K. Hu, P. Wang, and Y. Man, “Therapeutically directed osteogenic differentiation of induced pluripotent stem cell derived MSCs,” Acta Biomaterialia, vol. 74, pp. 222–235, 2018.

[71] H. Ramaraju and D. H. Kohn, “Cell and material-specific phage display peptides increase iPS-MSC mediated bone and vasculature formation in vivo,” Advanced Healthcare Materials, vol. 8, no. 9, article e1801356, 2019.

[72] W. TheinHan, J. Liu, M. Tang, W. Chen, L. Cheng, and H. H. K. Xu, “Induced pluripotent stem cell-derived mesenchymal stem cell seeding on biofunctionalized calcium phosphate cements,” Bone Research, vol. 1, no. 4, pp. 371–384, 2013.

[73] P. Wang, X. Liu, L. Zhao et al., “Bone tissue engineering via human induced pluripotent, umbilical cord and bone marrow mesenchymal stem cells in rat cranium,” Acta Biomaterialia, vol. 18, pp. 236–248, 2015.

[74] J. Xie, C. Peng, Q. Zhao et al., “Osteogenic differentiation and bone regeneration of iPSC-MSCs supported by a biomimetic nanofibrous scaffold,” Acta Biomaterialia, vol. 29, pp. 365–379, 2016.

[75] A. Al-Wahabi, T. Ser-Od, K. Inoue, K. Nakajima, K. Matsuzaka, and T. Inoue, “Topography enhances Runx 2 expression in outgrowing cells from iPSC cell-derived embryoid bodies,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol. 107, no. 7, pp. 2288–2296, 2019.

[76] M. Sladkova, M. Palmer, C. Öhman et al., “Fabrication of macroporous cement scaffolds using PEG particles: in vitro evaluation with induced pluripotent stem cell-derived mesenchymal progenitors,” Materials Science & Engineering C, Materials for Biological Applications, vol. 69, pp. 640–652, 2016.

[77] M. Tang, W. Chen, J. Liu, M. D. Weir, L. Cheng, and H. H. K. Xu, “Human induced pluripotent stem cell-derived mesenchymal stem cell seeding on calcium phosphate scaffold for bone regeneration,” Tissue Engineering Part A, vol. 20, no. 7-8, pp. 1295–1305, 2014.

[78] L. Wang, P. Wang, M. D. Weir, M. A. Reynolds, L. Zhao, and H. H. K. Xu, “Hydrogel fibers encapsulating human stem cells in an injectable calcium phosphate scaffold for bone tissue engineering,” Biomedical Materials, vol. 11, no. 6, article 65008, 2016.

[79] L. Wang, C. Zhang, C. Li et al., “Injectable calcium phosphate with hydrogel fibers encapsulating induced pluripotent, dental pulp and bone marrow stem cells for bone repair,” Materials Science & Engineering C, Materials for Biological Applications, vol. 69, pp. 1125–1136, 2016.

[80] O. H. Jeon, L. M. Panicker, Q. Lu, J. J. Chae, R. A. Feldman, and J. H. Elisseef, “Human iPSC-derived osteoblasts and osteoclasts together promote bone regeneration in 3D biomaterials,” Scientific Reports, vol. 6, no. 1, article 26761, 2016.

[81] G. Bilousova, D. H. Jun, K. B. King et al., “Osteoblasts derived from induced pluripotent stem cells form calcified structures in scaffolds both in vitro and in vivo,” Stem Cells, vol. 29, no. 2, pp. 206–216, 2011.

[82] A. L. Firth and J. X. J. Yuan, “‘Ether-à-go-go’ proliferation of iPSC-derived mesenchymal stem cells. Focus on ‘Regulation of cell proliferation of human induced pluripotent stem cell-derived mesenchymal stem cells via ether-à-go-go 1 (hEAG1) potassium channel’,” American Journal of Physiology-Cell Physiology, vol. 303, no. 2, pp. C113–C114, 2012.

[83] R. M. Guzzo, J. Gibson, R. H. Xu, F. Y. Lee, and H. Drissi, “Efficient differentiation of human iPSC-derived mesenchymal stem cells to chondroprogenitor cells,” Journal of Cellular Biochemistry, vol. 114, no. 2, pp. 480–490, 2013.

[84] Q. Lian, Y. Zhang, J. Zhang et al., “Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice,” Circulation, vol. 121, no. 9, pp. 1113–1123, 2010.

[85] J. Zhang, J. Guan, X. Qi et al., “Dimethylxaloylglycine promotes the angiogenic activity of mesenchymal stem cells derived from iPSCs via activation of the PI3K/Akt pathway for bone regeneration,” International Journal of Biological Sciences, vol. 12, no. 6, pp. 639–652, 2016.

[86] G. M. de Peppo, I. Marcos-Campos, D. J. Kahler et al., “Engineering bone tissue substitutes from human induced pluripotent stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 21, pp. 8680–8685, 2013.

[87] S. G. Hong, T. Winkler, C. Wu et al., “Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model,” Cell Reports, vol. 7, no. 4, pp. 1298–1309, 2014.

[88] K. Hynes, D. Menicanin, K. Mrozek, S. Gronthos, and P. M. Bartold, “Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines,” Stem Cells and Development, vol. 23, no. 10, pp. 1084–1096, 2014.

[89] R. Kang, Y. Luo, L. Zou et al., “Osteogenesis of human induced pluripotent stem cells derived mesenchymal stem cells on hydroxyapatite contained nanofibers,” RSC Advances, vol. 4, no. 11, pp. 5734–5739, 2014.
[90] L. Zou, Y. Luo, M. Chen et al., “A simple method for deriving functional MSCs and applied for osteogenesis in 3D scaffolds,” Scientific Reports, vol. 3, no. 1, article 2243, 2013.

[91] A. Nasu, M. Ikeya, T. Yamamoto et al., “Genetically matched human iPSCs reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin,” PLoS One, vol. 8, no. 1, article e53771, 2013.

[92] R. Chijimatsu, M. Ikeya, Y. Yasui et al., “Characterization of mesenchymal stem cell-like cells derived from human iPSCs via neural crest development and their application for osteochondral repair,” Stem Cells International, vol. 2017, Article ID 1960965, 18 pages, 2017.

[93] Y. Dogaki, S. Y. Lee, T. Niikura et al., “Efficient derivation of osteoprogenitor cells from induced pluripotent stem cells for bone regeneration,” International Orthopaedics, vol. 38, no. 9, pp. 1779–1785, 2014.

[94] F. A. A. Ishiy, R. D. Fanganiello, K. Griesi-Oliveira et al., “Improvement of in vitro osteogenic potential through differentiation of induced pluripotent stem cells from human exfoliated dental tissue towards mesenchymal-like stem cells,” Stem Cells International, vol. 2015, Article ID 249098, 9 pages, 2015.

[95] R. Kang, Y. Zhou, S. Tan et al., “Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity,” Stem Cell Research and Therapy, vol. 6, no. 1, 2015.

[96] S. I. Lepage, K. Nagy, H. K. Sung, R. A. Kandel, A. Nagy, and T. G. Koch, “Generation, characterization, and multilineage potency of mesenchymal-like progenitors derived from equine induced pluripotent stem cells,” Stem Cells and Development, vol. 25, no. 1, pp. 80–89, 2016.

[97] A. Ardeshiryalajimi, M. Soleimani, S. Hosseinkhani, K. Parivar, and P. Yaghmaei, “A comparative study of osteogenic differentiation human induced pluripotent stem cells and adipose tissue derived mesenchymal stem cells,” Cell Journal, vol. 16, no. 3, pp. 235–244, 2014.

[98] S.-H. Mao, C.-H. C.-T. Chen, and C.-H. C.-T. Chen, “Osteogenic potential of induced pluripotent stem cells from human adipose-derived stem cells,” Stem Cell Research & Therapy, vol. 10, no. 1, p. 303, 2019.

[99] M. D. Phillips, S. A. Kuznetsov, N. Cherman et al., “Directed differentiation of human induced pluripotent stem cells toward bone and cartilage: in vitro versus in vivo assays,” Stem Cells Translational Medicine, vol. 3, no. 7, pp. 867–878, 2014.

[100] B. Levi, J. S. Hyun, D. T. Montoro et al., “In vivo directed differentiation of pluripotent stem cells for skeletal regeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 50, pp. 20379–20384, 2012.

[101] Y. Deng, Y. Yang, and S. Wei, “Peptide-decorated nanofibrous niche augments in vitro directed osteogenic conversion of human pluripotent stem cells,” Biomacromolecules, vol. 18, no. 2, pp. 587–598, 2017.

[102] H. Kang, Y.-R. V. Shih, M. Nakasaki, H. Kabra, and S. Varghese, “Small molecule-driven direct conversion of human pluripotent stem cells into functional osteoblasts,” Science Advances, vol. 2, no. 8, article e1600691, 2016.

[103] S. Kawai, H. Yoshitomi, J. Sunaga et al., “In vitro bone-like nodules generated from patient-derived iPSCs recapitulate pathological bone phenotypes,” Nature Biomedical Engineering, vol. 3, no. 7, pp. 558–570, 2019.

[104] J.-H. Ye, Y.-J. Xu, J. Gao et al., “Critical-size calvarial bone defects healing in a mouse model with silk scaffolds and SATB2-modified iPSCs,” Biomaterials, vol. 32, no. 22, pp. 5065–5076, 2011.

[105] M. Wang, Y. Deng, P. Zhou et al., “In vitro culture and directed osteogenic differentiation of human pluripotent stem cells on peptides-decorated two-dimensional microenvironment,” ACS Applied Materials & Interfaces, vol. 7, no. 8, pp. 4560–4572, 2015.

[106] G.-Z. Jin, T.-H. Kim, J.-H. Kim et al., “Bone tissue engineering of induced pluripotent stem cells cultured with macrochanneled polymer scaffold,” Journal of Biomedical Materials Research Part A, vol. 101, no. 5, pp. 1283–1291, 2013.

[107] H. Kang, Y.-R. V. Shih, Y. Hwang et al., “Mineralized gelatin methacrylate-based matrices induce osteogenic differentiation of human induced pluripotent stem cells,” Acta Biomaterialia, vol. 10, no. 12, pp. 4961–4970, 2014.

[108] M. Sladkova, J. Cheng, M. Palmer et al., “Comparison of decellularized cow and human bone for engineering bone grafts with human induced pluripotent stem cells,” Tissue Engineering Part A, vol. 25, no. 3–4, pp. 288–301, 2019.

[109] H. Ochiai-Shino, H. Kato, T. Sawada et al., “A novel strategy for enrichment and isolation of osteoprogenitor cells from induced pluripotent stem cells based on surface marker combination,” PLoS One, vol. 9, no. 6, article e99534, 2014.

[110] A. Ardeshiryalajimi and M. Soleimani, “Enhanced growth and osteogenic differentiation of induced pluripotent stem cells by extremely low-frequency electromagnetic field,” Cellular and Molecular Biology, vol. 61, no. 1, pp. 36–41, 2015.

[111] S. Das and D. K. Das, “Anti-inflammatory responses of resveratrol,” Inflammation & Allergy Drug Targets, vol. 6, no. 3, pp. 168–173, 2007.

[112] C.-L. Kao, L.-K. Tai, S.-H. Chiou et al., “Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells,” Stem Cells and Development, vol. 19, no. 2, pp. 247–258, 2010.

[113] J. Park, J. Ries, K. Gelse et al., “Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes,” Gene Therapy, vol. 10, no. 13, pp. 1089–1098, 2003.

[114] K. Kanke, H. Masaki, T. Saito et al., “Stepwise differentiation of pluripotent stem cells into osteoblasts using four small molecules under serum-free and feeder-free conditions,” Stem Cell Reports, vol. 2, no. 6, pp. 751–760, 2014.

[115] Y. Wu, H. Sun, F. Song, C. Huang, and J. Wang, “Deletion of Alox 5 gene decreases osteogenic differentiation but increases adipogenic differentiation of mouse induced pluripotent stem cells,” Cell and Tissue Research, vol. 358, no. 1, pp. 135–147, 2014.

[116] A. Mirzaei, A. S. Moghadam, M. F. Abazari et al., “Comparison of osteogenic differentiation potential of induced pluripotent stem cells on 2D and 3D polyvinylidene fluoride scaffolds,” Journal of Cellular Physiology, vol. 234, no. 10, pp. 17854–17862, 2019.

[117] F. S. Hosseini, F. SoleimaniFar, A. Aidun et al., “Poly (3-hydroxybutyrate-co-3-hydroxyvalerate) improved osteogenic differentiation of the human induced pluripotent stem cells while considered as an artificial extracellular matrix,” Journal of Cellular Physiology, vol. 234, no. 7, pp. 11537–11544, 2019.
[118] F. S. Hosseini, F. Soleimanifar, A. Khojasteh, and A. Ardestehirajami, “Promoting osteogenic differentiation of human-induced pluripotent stem cells by releasing Wnt/β-catenin signaling activator from the nanofibers,” Journal of Cellular Biochemistry, vol. 120, no. 4, pp. 6339–6346, 2019.

[119] E. Saburi, M. Islami, S. Hosseinzadeh et al., “In vitro osteogenic differentiation potential of the human induced pluripotent stem cells augments when grown on Graphene oxide-modified nanofibers,” Gene, vol. 696, pp. 72–79, 2019.

[120] M. F. Abazari, F. Soleimanifar, M. Amini Fashkodi et al., “Improved osteogenic differentiation of human induced pluripotent stem cells cultured on polyvinylidene fluoride/collagen/platelet-rich plasma composite nanofibers,” Journal of Cellular Physiology, vol. 235, no. 2, pp. 1155–1164, 2020.

[121] J. Ji, X. Tong, X. Huang et al., “Sphere-shaped nano-hydroxyapatite/chitosan/gelatin 3D porous scaffolds increase proliferation and osteogenic differentiation of human induced pluripotent stem cells from gingival fibroblasts,” Biomedical Materials, vol. 10, no. 4, article 45005, 2015.

[122] K. Oudina, J. Paquet, A. Moya et al., “The paracrine effects of human induced pluripotent stem cells promote bone-like structures via the upregulation of BMP expression in a mouse ectopic model,” Scientific Reports, vol. 8, no. 1, article 17106, 2018.

[123] Y. Alaa El-Din, D. Sabry, A. H. Abdelrahman, and S. Fathy, “The paracrine effects of human induced pluripotent stem cells on induced salivary gland cancer in experimental rats,” Journal of Molecular and Cellular Biochemistry, vol. 94, no. 2, pp. 92–99, 2019.

[124] H. Ono, A. Obana, Y. Usami et al., “Regenerating salivary glands in the microenvironment of induced pluripotent stem cells,” Biomedical Research International, vol. 2015, Article ID 293570, 11 pages, 2015.

[125] J. Li, X. Yin, and Q. Luan, “Comparative study of periodontal differentiation propensity of induced pluripotent stem cells from different tissue origins,” Journal of Periodontology, vol. 89, no. 10, pp. 1230–1240, 2018.

[126] S. Hamano, A. Tomokiyo, D. Hasegawa et al., “Extracellular matrix from periodontal ligament cells could induce the differentiation of induced pluripotent stem cells to periodontal ligament stem cell-like cells,” Stem Cells and Development, vol. 27, no. 2, pp. 100–111, 2018.

[127] X. Duan, Q. Tu, J. Zhang et al., “Application of induced pluripotent stem (iPS) cells in periodontal tissue regeneration,” Journal of Cellular Physiology, vol. 226, no. 1, pp. 150–157, 2011.

[128] X. Yin, Y. Li, J. Li et al., “Generation and periodontal differentiation of human gingival fibroblasts- derived integration-free induced pluripotent stem cells,” Biochemical and Biophysical Research Communications, vol. 473, no. 3, pp. 726–732, 2016.

[129] X. Yin, P. Li, Y. Li, Y. Cai, J. Wen, and Q. Luan, “Growth/differentiation factor-5 promotes in vitro/vivo periodontal specific differentiation of induced pluripotent stem cell-derived mesenchymal stem cells,” Experimental and Therapeutic Medicine, vol. 14, no. 5, pp. 4111–4117, 2017.

[130] K.-H. Chien, Y.-L. Chang, M.-L. Wang et al., “Promoting induced pluripotent stem cell-driven biomaterialization and periodontal regeneration in rats with maxillary-molar defects using injectable BMP-6 hydrogel,” Scientific Reports, vol. 8, no. 1, p. 114, 2018.

[131] J. W. Li, X. H. Yin, and Q. X. Luan, “Comparative study of proliferative and periodontal differentiation propensity of induced pluripotent stem cells at different passages,” Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences, vol. 49, no. 1, pp. 16–24, 2017.

[132] K. Hynes, D. Menicanin, J. Han et al., “Mesenchymal stem cells from iPSCs facilitate periodontal regeneration,” Journal of Dental Research, vol. 92, no. 9, pp. 833–839, 2013.

[133] K. Hynes, R. Bright, V. Marino et al., “Potential of iPSC-derived mesenchymal stromal cells for treating periodontal disease,” Stem Cells International, vol. 2018, Article ID 2601945, 12 pages, 2018.

[134] H. Yang, R. M. Aprecio, X. Zhou et al., “Therapeutic effect of TSG-6 engineered iPSC-derived MSCs on experimental periodontitis in rats: a pilot study,” PLoS One, vol. 9, no. 6, article e100285, 2014.

[135] M. Arakaki, M. Ishikawa, T. Nakamura et al., “Role of epithelial-stem cell interactions during dental cell differentiation,” The Journal of Biological Chemistry, vol. 287, no. 13, pp. 10590–10601, 2012.

[136] K. Yoshida, J. Sato, R. Takai et al., “Differentiation of mouse iPSCs into ameloblast-like cells in cultures using medium conditioned by epithelial cell rests of Malassez and gelatin-coated dishes,” Medical Molecular Morphology, vol. 48, no. 3, pp. 138–145, 2015.

[137] A. N. Abdullah, S. Miyauchi, A. Onishi, K. Tanimoto, and K. Kato, “Differentiation of mouse-induced pluripotent stem cells into dental epithelial-like cells in the absence of added serum,” In Vitro Cellular & Developmental Biology Animal, vol. 55, no. 2, pp. 130–137, 2019.

[138] N. Ozeki, M. Mogi, R. Kawai et al., “Mouse-induced pluripotent stem cells differentiate into odontoblast-like cells with induction of altered adhesive and migratory phenotype of integrin,” PLoS One, vol. 8, no. 11, article e80026, 2013.

[139] N. Ozeki, N. Hase, H. Yamaguchi et al., “Polyphosphate induces matrix metalloproteinase-3-mediated proliferation of odontoblast-like cells derived from induced pluripotent stem cells,” Experimental Cell Research, vol. 333, no. 2, pp. 303–315, 2015.

[140] K. Otsu, R. Kishigami, A. Oikawa-Sasaki et al., “Differentiation of induced pluripotent stem cells into dental mesenchymal cells,” Stem Cells and Development, vol. 21, no. 7, pp. 1156–1164, 2012.

[141] D. Seki, N. Takeshita, T. Oyanagi et al., “Differentiation of odontoblast-like cells from mouse induced pluripotent stem cells by Pax 9 and Bmp 4 transfection,” Stem Cells Translational Medicine, vol. 4, no. 9, pp. 993–997, 2015.

[142] H. Xie, N. Dubey, W. Shim et al., “Functional odontoblastic-like cells derived from human iPSCs,” Journal of Dental Research, vol. 97, no. 1, pp. 77–83, 2018.

[143] J. Cai, Y. Zhang, P. Liu et al., “Generation of tooth-like structures from integration-free human urine induced pluripotent stem cells,” Cell Regeneration, vol. 2, no. 1, p. 2:6, 2013.

[144] L. Liu, Y.-F. Liu, J. Zhang, Y.-Z. Duan, and Y. Jin, “Ameloblasts serum-free conditioned medium: bone morphogenic protein 4-induced odontogenic differentiation of mouse induced pluripotent stem cells,” Journal of Tissue Engineering and Regenerative Medicine, vol. 10, no. 6, pp. 466–474, 2016.

[145] Y. Wen, F. Wang, W. Zhang et al., “Application of induced pluripotent stem cells in generation of a tissue-engineered tooth-like structure,” Tissue Engineering Part A, vol. 18, no. 15-16, pp. 1677–1685, 2012.

[146] Z. Liu, G. Zeng, Q. Qin, C. Sun, and L. Tan, “Smad 1/5 signal transduction regulates the ameloblastic differentiation of
induced pluripotent stem cells,” *Brazilian Oral Research*, vol. 34, article e006, 2020.

[147] S. Nori, Y. Okada, S. Nishimura et al., “Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition,” *Stem Cell Reports*, vol. 4, no. 3, pp. 360–373, 2015.

[148] M. J. Cooke, M. Stojkovic, and S. A. Przyborski, “Growth of teratomas derived from human pluripotent stem cells is influenced by the graft site,” *Stem Cells and Development*, vol. 15, no. 2, pp. 254–259, 2006.

[149] Q. Zhao, C. A. Gregory, R. H. Lee et al., “MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 112, no. 2, pp. 530–535, 2015.

[150] S. Yasuda, S. Kusakawa, T. Kuroda et al., “Tumorigenicity-associated characteristics of human iPSC lines,” *PLoS One*, vol. 13, no. 10, article e0205022, 2018.

[151] J.-H. Lee and S.-J. Seo, “Biomedical application of dental tissue-derived induced pluripotent stem cells,” *Stem Cells International*, vol. 2016, Article ID 9762465, 7 pages, 2016.

[152] M. Wernig, A. Meissner, J. P. Cassady, and R. Jaenisch, “c-Myc is dispensable for direct reprogramming of mouse fibroblasts,” *Cell Stem Cell*, vol. 2, no. 1, pp. 10–12, 2008.

[153] M. Silva, L. Daheron, H. Hurley et al., “Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies,” *Cell Stem Cell*, vol. 16, no. 1, pp. 13–17, 2015.

[154] J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., “Induced pluripotent stem cell lines derived from human somatic cells,” *Science*, vol. 318, no. 5858, pp. 1917–1920, 2007.

[155] K. Kim, A. Doi, B. Wen et al., “Epigenetic memory in induced pluripotent stem cells,” *Nature*, vol. 467, no. 7313, pp. 285–290, 2010.

[156] J. M. Polo, S. Liu, M. E. Figueroa et al., “Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells,” *Nature Biotechnology*, vol. 28, no. 8, pp. 848–855, 2010.

[157] L. G. Villa-Diaz, A. M. Ross, J. Lahann, and P. H. Krebsbach, "Concise review: the evolution of human pluripotent stem cell culture: from feeder cells to synthetic coatings," *Stem Cells*, vol. 31, no. 1, pp. 1–7, 2013.

[158] G. A. Erickson, S. R. Bolin, and J. G. Landgraf, "Viral contamination of fetal bovine serum used for tissue culture: risks and concerns," *Developments in Biological Standardization*, vol. 75, pp. 173–175, 1991.

[159] T. Takeda-Kawaguchi, K. Sugiyama, S. Chikusa et al., "Derivation of iPSCs after culture of human dental pulp cells under defined conditions," *PLoS One*, vol. 9, no. 12, article e115392, 2014.

[160] J. Gorecka, V. Kostiuk, A. Fereydooni et al., "The potential and limitations of induced pluripotent stem cells to achieve wound healing," *Stem Cell Research & Therapy*, vol. 10, no. 1, p. 87, 2019.

[161] J. Bilic and J. C. Izpisua Belmonte, "Concise review: induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart?" *Stem Cells*, vol. 30, no. 1, pp. 33–41, 2012.